AIP-related pituitary adenoma predisposition

Mendelian Pathograph 25 Show in embeddings browser hereditary cancer-predisposing syndrome

AIP-related pituitary adenoma predisposition is an autosomal dominant, incompletely penetrant hereditary pituitary tumor syndrome caused by germline pathogenic variants in AIP. It commonly presents within the familial isolated pituitary adenoma (FIPA) spectrum or as apparently sporadic young-onset somatotroph-predominant disease, with frequent pituitary macroadenomas, growth hormone excess, and clinical gigantism or acromegaly.

Ask OpenScientist

Ask a research question about AIP-related pituitary adenoma predisposition. OpenScientist will conduct autonomous deep research using the Disorder Mechanisms Knowledge Base and PubMed literature (typically 10-30 minutes).

Submitting...

Do not include personal health information in your question. Questions and results are cached in your browser's local storage.

🔗

Mappings

MONDO

MONDO:0007052 growth hormone secreting pituitary adenoma 1 Not Yet Curated

Retained as a close-match placeholder pending local OAK snapshot propagation of the minted exact anchor MONDO:1060231 ("AIP-related pituitary adenoma predisposition"), which was minted upstream via MONDO PR #10326 (merged 2026-06-17). Once MONDO:1060231 resolves locally (currently returns None in sqlite:obo:mondo), the top-level disease_term should be re-anchored to MONDO:1060231 and this skos:closeMatch demoted to a legacy mapping.

MONDO:0017824 familial isolated pituitary adenoma Not Yet Curated

AIP-related disease is a major molecular subset of familial isolated pituitary adenoma but does not cover all FIPA families.

👪

Inheritance

Autosomal dominant HP:0000006

AIP-related pituitary adenoma predisposition segregates as an autosomal dominant disorder with incomplete penetrance and variable tumor type.

Autosomal dominant inheritance Penetrance: INCOMPLETE Expressivity: VARIABLE

Show evidence (2 references)

PMID:23310926 SUPPORT Human Clinical

"AIP mutations cause a low penetrance autosomal dominant disease with often a distinct phenotype characterized by young-onset, aggressive, large GH, mixed GH and PRL or PRL-secreting adenomas."

This review directly supports autosomal dominant inheritance with reduced penetrance and variable endocrine tumor phenotype.

PMID:16728643 SUPPORT Human Clinical

"Typically, PAP patients do not display a strong family history of pituitary adenoma; thus, AIP is an example of a low-penetrance tumor susceptibility gene."

This original discovery study supports incomplete penetrance in AIP-related disease.

Discussions and Knowledge Gaps

Does altered AIP-AHR transcriptional signaling directly promote somatotroph tumor growth or invasiveness in human AIP-mutant pituitary adenomas, beyond the demonstrated cell-model effects on AHR target genes and ligand-dependent growth hormone secretion?

KNOWLEDGE GAP OPEN gap_aip_ahr_branch_tumor_growth_causality

Attached to

pathophysiology#Reduced AIP AHR/HSP90 co-chaperone binding function pathophysiology#Dysregulated AHR target-gene transcriptional response pathophysiology#Altered ligand-dependent growth hormone secretion phenotype#Growth hormone excess

The AIP-AHR branch now has a supported immediate outcome: altered AHR target-gene transcription and altered kynurenine-dependent GH secretion in GH3 cells. What remains unresolved is whether that branch is a causal driver of the human macroadenoma growth and invasiveness phenotype, rather than a measurable molecular/endocrine readout of AIP loss.

Show evidence (1 reference)

PMID:27080473 SUPPORT In Vitro

"Germline mutations in the aryl hydrocarbon receptor-interacting protein (AIP) gene predispose humans to pituitary adenomas through unknown molecular mechanisms."

This frames the AIP-AHR pathway as a mechanistic hypothesis while leaving the causal bridge to human pituitary tumor growth unresolved.

⚙

Pathophysiology

Germline AIP loss-of-function predisposition

Germline loss-of-function variants in AIP create constitutional susceptibility to pituitary adenoma formation, especially in the somatotroph lineage.

AIP hgnc:358 ↓ DECREASED

Genetic context AIP hgnc:358 variant_origin: GERMLINE allelic_hit_role: FIRST_HIT allelic_event: PATHOGENIC_VARIANT zygosity: HETEROZYGOUS functional_impact_category: LOSS_OF_FUNCTION

Constitutional heterozygous AIP loss-of-function is the inherited first hit that creates pituitary adenoma susceptibility.

pituitary gland UBERON:0000007

Downstream

Somatic second-hit AIP inactivation The germline AIP loss-of-function allele acts as the first ("inherited") hit; a somatic second hit at the wild-type AIP locus on 11q13 (loss of heterozygosity / large-scale chromosomal deletion) completes biallelic inactivation per the Knudson two-hit tumor-suppressor model.

Show evidence (2 references)

PMID:16728643 SUPPORT Human Clinical

"Combining chip-based technologies with genealogy data, we identified germline mutations in the aryl hydrocarbon receptor interacting protein (AIP) gene in individuals with pituitary adenoma predisposition (PAP)."

This discovery study establishes germline AIP mutation as the proximal cause of the pituitary adenoma predisposition syndrome.

PMID:17360484 SUPPORT Human Clinical

"Germ-line mutations in the aryl hydrocarbon receptor-interacting protein (AIP) gene cause pituitary adenoma predisposition (PAP)."

This international validation study confirms AIP as the core causal gene across multiple populations.

Somatic second-hit AIP inactivation

Completion of the Knudson two-hit tumor-suppressor model in AIP-related pituitary tumorigenesis: on the background of a constitutional germline AIP loss-of-function allele, a somatic second hit at the remaining wild-type AIP allele on 11q13 (loss of heterozygosity, frequently via a large-scale chromosomal deletion) eliminates residual AIP function in the tumor-initiating somatotroph clone.

AIP hgnc:358 ∅ ABSENT

Genetic context AIP hgnc:358 variant_origin: SOMATIC allelic_hit_role: SECOND_HIT allelic_event: DELETION allelic_event: LOSS_OF_HETEROZYGOSITY functional_impact_category: LOSS_OF_FUNCTION

Acquired loss of the remaining wild-type AIP allele in tumor tissue completes the second hit.

pituitary gland UBERON:0000007

Downstream

Biallelic AIP-deficient somatotroph state Somatic loss of the remaining AIP allele eliminates residual AIP function in the tumor-initiating somatotroph clone.

Show evidence (1 reference)

PMID:32336638 SUPPORT Human Clinical

"Analysis of the tumor tissue revealed a large-scale deletion on chromosome 11 overlapping with AIP leading to bi-allelic AIP loss."

This directly documents a somatic second hit (large-scale 11q deletion spanning AIP) producing biallelic AIP loss in the tumor, the defining event of the two-hit model in this disorder.

Biallelic AIP-deficient somatotroph state

In the tumor-initiating somatotroph clone, inherited and somatic AIP loss combine to create an AIP-deficient cellular state that rewires receptor, chaperone, cAMP, and cytokine-signaling programs.

somatotroph CL:0002312

AIP hgnc:358 ∅ ABSENT

Genetic context AIP hgnc:358 variant_origin: GERMLINE_AND_SOMATIC allelic_hit_role: BIALLELIC_INACTIVATION allelic_event: BIALLELIC_INACTIVATION functional_impact_category: LOSS_OF_FUNCTION

The tumor-initiating somatotroph clone has biallelic AIP loss through inherited and acquired inactivating events.

pituitary gland UBERON:0000007

Downstream

Reduced AIP AHR/HSP90 co-chaperone binding function Loss of AIP perturbs its AHR-binding and HSP90 co-chaperone interaction functions.

Defective GNAI2/GNAI3-mediated adenylate cyclase restraint AIP deficiency disrupts GNAI2 and GNAI3 function, weakening inhibitory G-protein restraint of adenylate cyclase and cAMP synthesis.

Disrupted AIP-dependent PDE4A cAMP-phosphodiesterase module AIP deficiency disrupts an AIP-PDE module that normally binds and modulates PDE4A-family cAMP phosphodiesterase control.

Reduced SSTR2 expression in AIP-mutant somatotrophs AIP-mutant somatotroph cells express less SSTR2, weakening the receptor target used by first-generation somatostatin analogs.

Reduced PLAGL1/ZAC1 tumor-suppressor signaling AIP-mutant somatotroph cells express less PLAGL1/ZAC1, reducing a tumor-suppressor program that normally restrains proliferation.

IL-6/STAT3 activation in AIP-mutant somatotrophs AIP-mutant somatotroph cells show increased IL-6 and phosphorylated STAT3, linking the AIP-deficient state to a cytokine-signaling program.

Show evidence (1 reference)

PMID:32336638 SUPPORT Human Clinical

"Coincident germline and somatic AIP mutations were likely causal in formation of a GH-secreting adenoma with an aggressive phenotype."

This supports the biallelic AIP-deficient tumor clone as the proximal disease-driving state.

Reduced AIP AHR/HSP90 co-chaperone binding function

AIP normally acts as a co-chaperone that binds the aryl hydrocarbon receptor and HSP90 chaperone machinery. AIP loss reduces this molecular binding function and disrupts handling of the latent AHR complex.

AIP hgnc:358

AHR hgnc:348

aryl hydrocarbon receptor binding GO:0017162 ↓ DECREASED Hsp90 protein binding GO:0051879 ↓ DECREASED

Downstream

Dysregulated AHR target-gene transcriptional response Disruption of AIP-dependent AHR complex handling dysregulates AHR target-gene transcriptional responses.

Show evidence (2 references)

PMID:16728643 SUPPORT Human Clinical

"AIP acts in cytoplasmic retention of the latent form of the aryl hydrocarbon receptor and also has other functions."

This directly supports disruption of AIP-dependent AHR complex handling as a component of disease biology.

PMID:27080473 SUPPORT In Vitro

"As 75% of AIP mutations disrupt the physical and/or functional interaction with AhR, we postulated that the tumorigenic potential of AIP mutations might result from altered AhR signaling."

This supports the AIP-AHR interaction as a mechanistic axis affected by pathogenic AIP variants.

Dysregulated AHR target-gene transcriptional response

AIP-dependent handling of the AHR complex is required for normal ligand-responsive AHR target-gene transcription; loss of AIP dysregulates this response, including CYP1B1 and AHRR expression after endogenous AHR ligand stimulation.

AHR hgnc:348

AHR-dependent transcriptional response GO:0006355 ↕ DYSREGULATED xenobiotic-response signaling GO:0009410 ↕ DYSREGULATED

Downstream

Altered ligand-dependent growth hormone secretion AIP-dependent disruption of AHR signaling affects kynurenine-dependent growth hormone secretion in pituitary GH3 cells.

Show evidence (1 reference)

PMID:27080473 SUPPORT In Vitro

"Gene expression analyses showed significant modifications in the expression of the AhR target genes CYP1B1 and AHRR in AIP-mutated fibroblasts, both before and after stimulation with the endogenous AhR ligand kynurenine."

This directly supports altered AHR target-gene transcription downstream of AIP mutation.

Altered ligand-dependent growth hormone secretion

In pituitary GH3 cells, mutant AIP expression or Aip knockdown changes the growth-hormone secretory response to the endogenous AHR ligand kynurenine. The direction and causal contribution of this AHR branch to clinical somatotroph tumor growth remain unresolved.

somatotroph CL:0002312

AIP hgnc:358 AHR hgnc:348

ligand-dependent growth hormone secretion GO:0030252 ↕ DYSREGULATED

Show evidence (1 reference)

PMID:27080473 SUPPORT In Vitro

"Both mutant AIP expression and knockdown of endogenous Aip affected the kynurenine-dependent GH secretion of GH3 cells."

This supports altered ligand-dependent GH secretion as a downstream readout of AIP-AHR pathway disruption in a pituitary cell model.

Defective GNAI2/GNAI3-mediated adenylate cyclase restraint

AIP deficiency impairs GNAI2/GNAI3 proteins that normally inhibit adenylate cyclase, decreasing inhibitory control over cAMP synthesis in somatotroph cells.

somatotroph CL:0002312

GNAI2 hgnc:4385 GNAI3 hgnc:4387

adenylate cyclase-modulating GPCR signaling GO:0007188 ⚠ ABNORMAL

Downstream

Increased cAMP/PKA signaling in somatotrophs Failure of GNAI2/GNAI3-mediated adenylate cyclase restraint elevates cAMP signaling in AIP-deficient somatotrophs.

Show evidence (2 references)

PMID:24662816 SUPPORT In Vitro

"AIP deficiency leads to elevated cAMP concentrations through defective Gαi-2 and Gαi-3 proteins that normally inhibit cAMP synthesis."

This supports increased cAMP signaling as a central consequence of AIP deficiency.

PMID:24662816 SUPPORT In Vitro

"This study implies for the first time that a failure to inhibit cAMP synthesis through dysfunctional Gαi signaling underlies the development of GH-secreting pituitary adenomas in AIP mutation carriers."

This directly links defective Gi-cAMP control to the somatotroph-predominant tumor phenotype seen in AIP mutation carriers.

Disrupted AIP-dependent PDE4A cAMP-phosphodiesterase module

AIP normally participates as a co-chaperone/scaffold in a phosphodiesterase module that includes PDE4A isoforms. This module links AIP to compartmentalized cAMP control by binding PDE enzymes and modulating PDE4A-family cAMP phosphodiesterase activity/localization; loss of AIP disrupts that module.

somatotroph CL:0002312

AIP hgnc:358 PDE4A hgnc:8780

AIP-dependent regulation of PDE-mediated cyclic nucleotide catabolism GO:0030805 ⚠ ABNORMAL

AIP binding to phosphodiesterase enzyme GO:0019899 ↓ DECREASED AIP-PDE4A protein complex binding GO:0044877 ↕ DYSREGULATED

Downstream

Reduced PDE4A-mediated cAMP catabolism Loss of the AIP-dependent PDE4A module reduces the PDE4A4/PDE4A8 compensation that normally degrades cAMP in somatotroph tumors.

Show evidence (2 references)

PMID:28427099 SUPPORT In Vitro

"the well-known interaction between AIP and 2 different isoforms of phosphodiesterases (PDEs), PDE2A3 and PDE4A5, is of particular interest"

This review establishes the AIP-PDE4A5 (PDE4A4) and AIP-PDE2A3 interactions as a recognized component of the cAMP-PDE axis disturbed in AIP-mutant pituitary disease.

PMID:28427099 SUPPORT In Vitro

"While the interaction with over-expressed AIP does not seem to affect PDE2A3 function, the reported effect on PDE4A5 is, in contrast, reduced enzymatic activity."

This supports the more specific interpretation that the AIP-PDE4A module modulates PDE4A-family enzymatic function rather than representing a generic protein-protein contact only.

Reduced PDE4A-mediated cAMP catabolism

AIP-mutant somatotroph tumors show lower PDE4A4/PDE4A8 protein expression, reducing cAMP degradation and contributing to a cAMP-PDE pathway disturbance.

somatotroph CL:0002312

PDE4A hgnc:8780

PDE4A-mediated cAMP catabolism GO:0006198 ↓ DECREASED

PDE4A cAMP-specific phosphodiesterase activity GO:0004115 ↓ DECREASED

Downstream

Increased cAMP/PKA signaling in somatotrophs Reduced PDE4A4/PDE4A8 expression limits cAMP degradation, feeding into elevated cAMP/PKA signaling.

Show evidence (2 references)

PMID:29729370 SUPPORT Human Clinical

"Confocal immunofluorescence analysis showed that both PDE4A8 and PDE4A4 had lower expression in AIP-mutated somatotropinoma samples compared to sporadic GH-secreting tumours"

This directly supports reduced PDE4A4 and PDE4A8 protein expression in AIP-mutant somatotropinomas relative to sporadic GH-secreting tumors.

PMID:29729370 SUPPORT Human Clinical

"These data point to a unique disturbance of the cAMP-PDE pathway in AIP-mutation positive adenomas, which may help to explain their well-described poor response to somatostatin analogues."

This explicitly links the cAMP-PDE pathway disturbance in AIP-mutant tumors to their somatostatin-analog resistance.

Increased cAMP/PKA signaling in somatotrophs

Convergent GNAI2/GNAI3 and PDE4A defects leave cAMP/PKA signaling elevated in AIP-deficient somatotrophs, promoting GH-secreting pituitary adenoma biology.

somatotroph CL:0002312

cAMP-mediated signaling GO:0141156 ↑ INCREASED

Downstream

Pituitary macroadenoma Elevated cAMP/PKA signaling contributes to development of large, GH-secreting pituitary adenomas in AIP mutation carriers.

Growth hormone excess The AIP-deficient cAMP program favors a GH-secreting somatotroph tumor phenotype.

Pituitary adenoma Defective cAMP restraint in AIP mutation carriers contributes to GH-secreting pituitary adenoma development within the AIP-related predisposition spectrum.

Hyperprolactinemia AIP-related adenomas include mixed GH/PRL-secreting and PRL-secreting tumors; the specific mechanistic bridge from the somatotroph cAMP branch to prolactin excess remains unresolved.

Show evidence (1 reference)

PMID:24662816 SUPPORT In Vitro

This supports elevated cAMP signaling as a proximal driver of GH-secreting pituitary adenoma development in AIP mutation carriers.

Reduced SSTR2 expression in AIP-mutant somatotrophs

Pathogenic AIP variants reduce SSTR2 expression in somatotroph cells, weakening receptor-level sensitivity to first-generation somatostatin analogs.

somatotroph CL:0002312

SSTR2 hgnc:11331

Show evidence (2 references)

PMID:30447469 SUPPORT In Vitro

"the experimental group cells expressed less Sstr2 (a prerequisite for the responsiveness to somatostatin analogues) and Zac1 (tumor suppressor gene), but more IL-6 and phosphorylated-Stat3 (GH-secretion related)."

This directly supports reduced SSTR2 expression as a discrete downstream effect of pathogenic AIP variation.

PMID:22659247 SUPPORT Human Clinical

"Somatotroph adenomas harboring aryl hydrocarbon receptor interacting protein (AIP) mutations respond less well to somatostatin analogs"

This human clinical observation supports the treatment-response relevance of SSTR2-linked AIP-mutant tumor biology.

Reduced PLAGL1/ZAC1 tumor-suppressor signaling

Pathogenic AIP variants reduce PLAGL1/ZAC1 expression in somatotroph cells, weakening a tumor-suppressor program that normally restrains growth.

somatotroph CL:0002312

PLAGL1 (ZAC1) hgnc:9046

Downstream

Increased somatotroph proliferation and invasiveness Loss of the ZAC1 tumor-suppressor program contributes to increased proliferation and invasion in AIP-mutant somatotroph cells.

Show evidence (1 reference)

PMID:30447469 SUPPORT In Vitro

This directly supports reduced PLAGL1/ZAC1 expression as a discrete downstream effect of pathogenic AIP variation.

IL-6/STAT3 activation in AIP-mutant somatotrophs

AIP-mutant somatotroph cells show increased IL-6 and phosphorylated STAT3, a cytokine-signaling branch associated with GH secretion, proliferation, and invasiveness.

somatotroph CL:0002312

IL6 hgnc:6018 STAT3 hgnc:11364

IL-6/STAT3 signaling GO:0070102 ↑ INCREASED

Downstream

Increased somatotroph proliferation and invasiveness IL-6/phospho-STAT3 activation contributes to the proliferative and invasive AIP-mutant somatotroph phenotype.

Growth hormone excess IL-6/phospho-STAT3 activation is associated with GH secretion in AIP-mutant somatotroph cells.

Show evidence (2 references)

PMID:30447469 SUPPORT In Vitro

This in vitro study with a pathogenic AIP variant directly demonstrates increased IL-6 and phospho-STAT3 in AIP-mutant somatotroph cells.

PMID:30447469 SUPPORT In Vitro

"The novel AIP mutation c.512C>T (p.T171I) is a pathogenic variant that promoted cell proliferation, invasiveness, and GH secretion through regulation of Sstr2, Zac1, and IL-6/phosphorylated-Stat3 expression."

This identifies IL-6/phospho-STAT3 regulation as part of the mechanistic route by which an AIP loss-of-function variant promotes proliferation, invasion, and GH secretion.

Increased somatotroph proliferation and invasiveness

The AIP-mutant SSTR2/ZAC1/IL-6/STAT3 expression program promotes somatotroph proliferation and invasion, contributing to the aggressive, large adenoma phenotype.

somatotroph CL:0002312

somatotroph proliferation GO:0008283 ↑ INCREASED

Downstream

Pituitary macroadenoma Increased somatotroph proliferation and invasion contribute to large, aggressive pituitary adenomas.

Headache Large AIP-associated pituitary macroadenomas can cause headache through sellar mass effect.

Visual field defect Suprasellar extension of large AIP-associated pituitary tumors can cause visual field loss by optic apparatus compression.

Show evidence (1 reference)

PMID:30447469 SUPPORT In Vitro

This directly supports increased proliferation and invasion downstream of the AIP-mutant expression program.

⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.

●

Phenotypes

Eye 1

Visual field defect Visual field defect HP:0001123

Show evidence (1 reference)

PMID:22720333 SUPPORT Human Clinical

"Clinical findings result from excess hormone secretion, lack of hormone secretion, and/or mass effects (e.g., headaches, visual field loss)."

This GeneReviews summary supports visual field loss as a mass-effect manifestation of large AIP-associated pituitary tumors.

Nervous System 1

Headache Headache HP:0002315

Show evidence (1 reference)

PMID:22720333 SUPPORT Human Clinical

"Clinical findings result from excess hormone secretion, lack of hormone secretion, and/or mass effects (e.g., headaches, visual field loss)."

This GeneReviews summary supports headache as a common mass-effect manifestation of AIP-associated pituitary tumors.

Other 4

Pituitary adenoma Pituitary adenoma HP:0002893

Show evidence (1 reference)

PMID:17360484 SUPPORT Human Clinical

"Germ-line mutations in the aryl hydrocarbon receptor-interacting protein (AIP) gene cause pituitary adenoma predisposition (PAP)."

This validates pituitary adenoma predisposition as the core clinical manifestation of germline AIP disease.

Pituitary macroadenoma Pituitary macroadenoma HP:0025693

Sequelae: Headache Visual field defect

Show evidence (2 references)

PMID:17893250 SUPPORT Human Clinical

"Patients with FIPA are significantly younger at diagnosis and have significantly larger pituitary adenomas than matched sporadic pituitary adenoma counterparts."

This supports the tendency toward larger pituitary tumors in the FIPA setting that includes AIP-related disease.

PMID:21753072 SUPPORT Human Clinical

"Germline AIPmut occur in 11.7% of patients <30 years with sporadic pituitary macroadenomas and in 20.5% of pediatric patients."

This focused young-onset cohort supports macroadenoma as a common presenting tumor form in AIP mutation carriers.

Growth hormone excess Elevated circulating growth hormone concentration HP:0000845

Show evidence (1 reference)

PMID:23310926 SUPPORT Human Clinical

"AIP mutations cause a low penetrance autosomal dominant disease with often a distinct phenotype characterized by young-onset, aggressive, large GH, mixed GH and PRL or PRL-secreting adenomas."

This review supports growth hormone excess as a dominant endocrine feature of AIP-related pituitary adenoma predisposition.

Hyperprolactinemia Increased circulating prolactin concentration HP:0000870

Show evidence (1 reference)

PMID:23310926 SUPPORT Human Clinical

"AIP mutations cause a low penetrance autosomal dominant disease with often a distinct phenotype characterized by young-onset, aggressive, large GH, mixed GH and PRL or PRL-secreting adenomas."

This review supports recurrent prolactin excess within the AIP-related adenoma spectrum.

🧬

Genetic Associations

AIP (Germline loss-of-function predisposition with somatic second-hit tumor-suppressor inactivation)

Gene: AIP hgnc:358 relationship_type: SUSCEPTIBILITY variant_origin: GERMLINE_AND_SOMATIC

Autosomal dominant

Show evidence (2 references)

PMID:16728643 SUPPORT Human Clinical

This discovery study establishes germline AIP loss-of-function as the core causal genetic lesion.

PMID:23310926 SUPPORT Human Clinical

"identification of a mutation in this gene in 20% of FIPA families"

This review supports AIP as a major molecular contributor within FIPA and early-onset simplex somatotroph adenoma.

💊

Medical Actions

Transsphenoidal surgery and multimodal local control

Action: surgical procedure MAXO:0000004

Large AIP-associated somatotropinomas are usually treated with transsphenoidal surgery, with adjuvant medical therapy and radiotherapy considered for residual or invasive disease.

Mechanism Target:

MODULATES Increased somatotroph proliferation and invasiveness — Transsphenoidal resection removes tumor tissue produced by the proliferative, invasive somatotroph clone and reduces mass effect.

Target Phenotypes: Pituitary macroadenoma HP:0025693 Growth hormone excess HP:0000845 Headache HP:0002315 Visual field defect HP:0001123

Show evidence (1 reference)

PMID:22720333 SUPPORT Human Clinical

"Large somatotropinomas are treated with transsphenoidal surgery, medical therapy, and/or radiotherapy."

This supports surgery as the central local treatment modality for large AIP-associated somatotropinomas, with multimodal escalation as needed.

First-generation somatostatin analog therapy with reduced response

Action: Pharmacotherapy NCIT:C15986

AIP-mutant somatotroph tumors frequently respond less well to first-generation somatostatin receptor ligands such as octreotide or lanreotide, often necessitating alternative or combination therapy.

Mechanism Target:

MODULATES Reduced SSTR2 expression in AIP-mutant somatotrophs — First-generation somatostatin analog response depends on SSTR2; reduced SSTR2 expression explains the diminished response in AIP-mutant tumors.

MODULATES Reduced PDE4A-mediated cAMP catabolism — The AIP-mutant cAMP-PDE disturbance may contribute to poor somatostatin-analog response.

Target Phenotypes: Growth hormone excess HP:0000845

Show evidence (2 references)

PMID:22659247 SUPPORT Human Clinical

"Somatotroph adenomas harboring aryl hydrocarbon receptor interacting protein (AIP) mutations respond less well to somatostatin analogs"

This directly supports reduced effectiveness of first-generation somatostatin analog treatment in AIP-mutant somatotroph tumors.

PMID:29953972 SUPPORT Human Clinical

"AIP mutations are found in 20-25% cases and cause aggressive somatotropinomas, often resistant to somatostatin analogues."

This pediatric clinical report reinforces somatostatin analogue resistance as a management hallmark of AIP-associated somatotropinomas.

Dopamine agonist and pegvisomant escalation for resistant disease

Action: Pharmacotherapy NCIT:C15986

Mixed GH/PRL tumors or resistant somatotropinomas may require dopamine agonists and GH receptor antagonist therapy as part of multimodal disease control.

Target Phenotypes: Growth hormone excess HP:0000845 Increased circulating prolactin concentration HP:0000870

Show evidence (2 references)

PMID:22720333 SUPPORT Human Clinical

"GH receptor antagonists, and dopamine agonists), surgery, and/or radiotherapy."

This GeneReviews summary supports dopamine agonists and GH receptor antagonists within standard multimodal treatment of GH-producing tumors.

PMID:29953972 SUPPORT Human Clinical

"They were initially treated with a long-acting somatostatin analogue (octreotide LAR 30 mg/month) and cabergoline as a dopamine agonist, with the later addition of pegvisomant titrated up to 20 mg/day and with radiotherapy for long-term control."

This pediatric AIP-mutant cohort supports escalation to cabergoline and pegvisomant in resistant disease.

Radiotherapy for residual or recurrent tumor control

Action: radiation therapy MAXO:0000014

Radiotherapy remains an accepted adjunct for residual, recurrent, or inoperable AIP-associated pituitary tumors when surgery and medical therapy are insufficient.

Mechanism Target:

INHIBITS Increased somatotroph proliferation and invasiveness — Radiotherapy is used for residual, recurrent, or inoperable tumor control when proliferative tumor tissue remains after surgery and medical therapy.

Target Phenotypes: Pituitary macroadenoma HP:0025693

Show evidence (1 reference)

PMID:29953972 SUPPORT Human Clinical

This supports radiotherapy as part of multimodal long-term control in resistant AIP-mutant somatotropinomas.

{ }

Source YAML

click to show

name: AIP-related pituitary adenoma predisposition
creation_date: '2026-04-16T19:22:53Z'
updated_date: '2026-05-17T00:00:00Z'
category: Mendelian
categories:
- Hereditary Cancer Syndrome
- Cancer Predisposition Syndrome
- Endocrine Neoplasia
parents:
- hereditary cancer-predisposing syndrome
disease_term:
  preferred_term: AIP-related pituitary adenoma predisposition
synonyms:
- AIP-related familial isolated pituitary adenoma
- AIP-positive familial isolated pituitary adenoma
- AIP-related pituitary adenoma predisposition syndrome
mappings:
  mondo_mappings:
  - term:
      id: MONDO:0007052
      label: growth hormone secreting pituitary adenoma 1
    mapping_predicate: skos:closeMatch
    mapping_source: MONDO
    mapping_justification: >-
      Retained as a close-match placeholder pending local OAK snapshot
      propagation of the minted exact anchor MONDO:1060231 ("AIP-related
      pituitary adenoma predisposition"), which was minted upstream via
      MONDO PR #10326 (merged 2026-06-17). Once MONDO:1060231 resolves
      locally (currently returns None in sqlite:obo:mondo), the top-level
      disease_term should be re-anchored to MONDO:1060231 and this
      skos:closeMatch demoted to a legacy mapping.
    tracked_issues:
    - url: https://github.com/monarch-initiative/mondo/issues/10131
      title: AIP-related pituitary adenoma predisposition
      tracked_issue_role: ontology_term_request
      tracked_issue_status: MERGED
      notes: >-
        MONDO NTR #10131 was resolved via MONDO PR #10326 (merged
        2026-06-17), minting MONDO:1060231 ("AIP-related pituitary adenoma
        predisposition") as the exact gene-related syndrome anchor.
        Re-anchoring of the dismech top-level disease_term is pending
        propagation of MONDO:1060231 into the local sqlite:obo:mondo
        snapshot (term still returns None as of 2026-06-30).
  - term:
      id: MONDO:0017824
      label: familial isolated pituitary adenoma
    mapping_predicate: skos:relatedMatch
    mapping_source: MONDO
    mapping_justification: >-
      AIP-related disease is a major molecular subset of familial isolated
      pituitary adenoma but does not cover all FIPA families.
description: >-
  AIP-related pituitary adenoma predisposition is an autosomal dominant,
  incompletely penetrant hereditary pituitary tumor syndrome caused by germline
  pathogenic variants in AIP. It commonly presents within the familial isolated
  pituitary adenoma (FIPA) spectrum or as apparently sporadic young-onset
  somatotroph-predominant disease, with frequent pituitary macroadenomas,
  growth hormone excess, and clinical gigantism or acromegaly.
inheritance:
- name: Autosomal dominant
  inheritance_term:
    preferred_term: Autosomal dominant inheritance
    term:
      id: HP:0000006
      label: Autosomal dominant inheritance
  penetrance: INCOMPLETE
  expressivity: VARIABLE
  description: >-
    AIP-related pituitary adenoma predisposition segregates as an autosomal
    dominant disorder with incomplete penetrance and variable tumor type.
  evidence:
  - reference: PMID:23310926
    reference_title: "Familial isolated pituitary adenomas: an emerging clinical entity."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      AIP mutations cause a low penetrance autosomal dominant disease with often
      a distinct phenotype characterized by young-onset, aggressive, large GH,
      mixed GH and PRL or PRL-secreting adenomas.
    explanation: >-
      This review directly supports autosomal dominant inheritance with reduced
      penetrance and variable endocrine tumor phenotype.
  - reference: PMID:16728643
    reference_title: "Pituitary adenoma predisposition caused by germline mutations in the AIP gene."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Typically, PAP patients do not display a strong family history of
      pituitary adenoma; thus, AIP is an example of a low-penetrance tumor
      susceptibility gene.
    explanation: >-
      This original discovery study supports incomplete penetrance in AIP-related
      disease.
progression:
- phase: Childhood-to-young-adult pituitary adenoma presentation phase
  age_range: usually first to third decade
  notes: >-
    AIP-related disease commonly presents early, often before age 30 to 35
    years, with large functioning pituitary adenomas that may arise in FIPA
    kindreds or appear simplex at diagnosis.
  evidence:
  - reference: PMID:23310926
    reference_title: "Familial isolated pituitary adenomas: an emerging clinical entity."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      AIP mutations cause a low penetrance autosomal dominant disease with often
      a distinct phenotype characterized by young-onset, aggressive, large GH,
      mixed GH and PRL or PRL-secreting adenomas.
    explanation: >-
      This review supports the characteristic early presentation of large,
      aggressive pituitary adenomas in AIP mutation carriers.
  - reference: PMID:21753072
    reference_title: "High prevalence of AIP gene mutations following focused screening in young patients with sporadic pituitary macroadenomas."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Germline AIPmut occur in 11.7% of patients <30 years with sporadic
      pituitary macroadenomas and in 20.5% of pediatric patients.
    explanation: >-
      This prospective series supports early presentation of AIP-related disease
      in young and pediatric macroadenoma cohorts.
pathophysiology:
- name: Germline AIP loss-of-function predisposition
  description: >-
    Germline loss-of-function variants in AIP create constitutional
    susceptibility to pituitary adenoma formation, especially in the
    somatotroph lineage.
  gene:
    preferred_term: AIP
    modifier: DECREASED
    term:
      id: hgnc:358
      label: AIP
  genetic_context:
    gene:
      preferred_term: AIP
      term:
        id: hgnc:358
        label: AIP
    variant_origin: GERMLINE
    allelic_hit_role: FIRST_HIT
    allelic_events:
    - PATHOGENIC_VARIANT
    zygosity: HETEROZYGOUS
    functional_impact_category: LOSS_OF_FUNCTION
    description: >-
      Constitutional heterozygous AIP loss-of-function is the inherited first
      hit that creates pituitary adenoma susceptibility.
  locations:
  - preferred_term: pituitary gland
    term:
      id: UBERON:0000007
      label: pituitary gland
  evidence:
  - reference: PMID:16728643
    reference_title: "Pituitary adenoma predisposition caused by germline mutations in the AIP gene."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Combining chip-based technologies with genealogy data, we identified
      germline mutations in the aryl hydrocarbon receptor interacting protein
      (AIP) gene in individuals with pituitary adenoma predisposition (PAP).
    explanation: >-
      This discovery study establishes germline AIP mutation as the proximal
      cause of the pituitary adenoma predisposition syndrome.
  - reference: PMID:17360484
    reference_title: "Molecular diagnosis of pituitary adenoma predisposition caused by aryl hydrocarbon receptor-interacting protein gene mutations."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Germ-line mutations in the aryl hydrocarbon receptor-interacting protein
      (AIP) gene cause pituitary adenoma predisposition (PAP).
    explanation: >-
      This international validation study confirms AIP as the core causal gene
      across multiple populations.
  downstream:
  - target: Somatic second-hit AIP inactivation
    description: >-
      The germline AIP loss-of-function allele acts as the first ("inherited")
      hit; a somatic second hit at the wild-type AIP locus on 11q13 (loss of
      heterozygosity / large-scale chromosomal deletion) completes biallelic
      inactivation per the Knudson two-hit tumor-suppressor model.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:32336638
      reference_title: "Large-scale second-hit AIP deletion causing a pediatric growth hormone-secreting pituitary adenoma: Case report and review of literature."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        Whole-exome sequencing showed a heterozygous germline mutation in the
        AIP gene suggesting pituitary adenoma predisposition. Analysis of the
        tumor tissue revealed a large-scale deletion on chromosome 11
        overlapping with AIP leading to bi-allelic AIP loss.
      explanation: >-
        This documents the germline AIP first hit followed by a somatic
        large-scale 11q deletion as the second hit, supporting progression
        from constitutional predisposition to biallelic somatic inactivation.
- name: Somatic second-hit AIP inactivation
  description: >-
    Completion of the Knudson two-hit tumor-suppressor model in AIP-related
    pituitary tumorigenesis: on the background of a constitutional germline
    AIP loss-of-function allele, a somatic second hit at the remaining
    wild-type AIP allele on 11q13 (loss of heterozygosity, frequently via a
    large-scale chromosomal deletion) eliminates residual AIP function in the
    tumor-initiating somatotroph clone.
  gene:
    preferred_term: AIP
    modifier: ABSENT
    term:
      id: hgnc:358
      label: AIP
  genetic_context:
    gene:
      preferred_term: AIP
      term:
        id: hgnc:358
        label: AIP
    variant_origin: SOMATIC
    allelic_hit_role: SECOND_HIT
    allelic_events:
    - DELETION
    - LOSS_OF_HETEROZYGOSITY
    functional_impact_category: LOSS_OF_FUNCTION
    description: >-
      Acquired loss of the remaining wild-type AIP allele in tumor tissue
      completes the second hit.
  locations:
  - preferred_term: pituitary gland
    term:
      id: UBERON:0000007
      label: pituitary gland
  evidence:
  - reference: PMID:32336638
    reference_title: "Large-scale second-hit AIP deletion causing a pediatric growth hormone-secreting pituitary adenoma: Case report and review of literature."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Analysis of the tumor tissue revealed a large-scale deletion on
      chromosome 11 overlapping with AIP leading to bi-allelic AIP loss.
    explanation: >-
      This directly documents a somatic second hit (large-scale 11q deletion
      spanning AIP) producing biallelic AIP loss in the tumor, the defining
      event of the two-hit model in this disorder.
  downstream:
  - target: Biallelic AIP-deficient somatotroph state
    description: >-
      Somatic loss of the remaining AIP allele eliminates residual AIP
      function in the tumor-initiating somatotroph clone.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:32336638
      reference_title: "Large-scale second-hit AIP deletion causing a pediatric growth hormone-secreting pituitary adenoma: Case report and review of literature."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        Coincident germline and somatic AIP mutations were likely causal in
        formation of a GH-secreting adenoma with an aggressive phenotype.
      explanation: >-
        This links completed biallelic (germline + somatic) AIP loss to
        formation of the GH-secreting somatotroph adenoma.
- name: Biallelic AIP-deficient somatotroph state
  description: >-
    In the tumor-initiating somatotroph clone, inherited and somatic AIP loss
    combine to create an AIP-deficient cellular state that rewires receptor,
    chaperone, cAMP, and cytokine-signaling programs.
  gene:
    preferred_term: AIP
    modifier: ABSENT
    term:
      id: hgnc:358
      label: AIP
  genetic_context:
    gene:
      preferred_term: AIP
      term:
        id: hgnc:358
        label: AIP
    variant_origin: GERMLINE_AND_SOMATIC
    allelic_hit_role: BIALLELIC_INACTIVATION
    allelic_events:
    - BIALLELIC_INACTIVATION
    functional_impact_category: LOSS_OF_FUNCTION
    description: >-
      The tumor-initiating somatotroph clone has biallelic AIP loss through
      inherited and acquired inactivating events.
  cell_types:
  - preferred_term: somatotroph
    term:
      id: CL:0002312
      label: somatotroph
  locations:
  - preferred_term: pituitary gland
    term:
      id: UBERON:0000007
      label: pituitary gland
  evidence:
  - reference: PMID:32336638
    reference_title: "Large-scale second-hit AIP deletion causing a pediatric growth hormone-secreting pituitary adenoma: Case report and review of literature."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Coincident germline and somatic AIP mutations were likely causal in
      formation of a GH-secreting adenoma with an aggressive phenotype.
    explanation: >-
      This supports the biallelic AIP-deficient tumor clone as the proximal
      disease-driving state.
  downstream:
  - target: Reduced AIP AHR/HSP90 co-chaperone binding function
    description: >-
      Loss of AIP perturbs its AHR-binding and HSP90 co-chaperone interaction
      functions.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:16728643
      reference_title: "Pituitary adenoma predisposition caused by germline mutations in the AIP gene."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        AIP acts in cytoplasmic retention of the latent form of the aryl
        hydrocarbon receptor and also has other functions.
      explanation: >-
        This provides direct evidence that AIP normally participates in AHR
        complex handling, supporting disruption of that interaction in the
        disease state.
  - target: Defective GNAI2/GNAI3-mediated adenylate cyclase restraint
    description: >-
      AIP deficiency disrupts GNAI2 and GNAI3 function, weakening inhibitory
      G-protein restraint of adenylate cyclase and cAMP synthesis.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:24662816
      reference_title: "AIP inactivation leads to pituitary tumorigenesis through defective Gαi-cAMP signaling."
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: >-
        AIP deficiency leads to elevated cAMP concentrations through defective
        Gαi-2 and Gαi-3 proteins that normally inhibit cAMP synthesis.
      explanation: >-
        This mechanistic study links AIP deficiency to defective GNAI2/GNAI3
        restraint of cAMP synthesis.
  - target: Disrupted AIP-dependent PDE4A cAMP-phosphodiesterase module
    description: >-
      AIP deficiency disrupts an AIP-PDE module that normally binds and
      modulates PDE4A-family cAMP phosphodiesterase control.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:28427099
      reference_title: "Role of Phosphodiesterases on the Function of Aryl Hydrocarbon Receptor-Interacting Protein (AIP) in the Pituitary Gland and on the Evaluation of AIP Gene Variants."
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: >-
        the well-known interaction between AIP and 2 different isoforms of
        phosphodiesterases (PDEs), PDE2A3 and PDE4A5, is of particular interest
      explanation: >-
        This supports an AIP-PDE enzyme-binding module relevant to cAMP control
        in pituitary AIP biology.
  - target: Reduced SSTR2 expression in AIP-mutant somatotrophs
    description: >-
      AIP-mutant somatotroph cells express less SSTR2, weakening the receptor
      target used by first-generation somatostatin analogs.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:30447469
      reference_title: "A Novel Mutation of Aryl Hydrocarbon Receptor Interacting Protein Gene Associated with Familial Isolated Pituitary Adenoma Mediates Tumor Invasion and Growth Hormone Hypersecretion."
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: >-
        the experimental group cells expressed less Sstr2 (a prerequisite for
        the responsiveness to somatostatin analogues) and Zac1 (tumor suppressor
        gene), but more IL-6 and phosphorylated-Stat3 (GH-secretion related).
      explanation: >-
        This directly links pathogenic AIP variation to lower SSTR2 expression.
  - target: Reduced PLAGL1/ZAC1 tumor-suppressor signaling
    description: >-
      AIP-mutant somatotroph cells express less PLAGL1/ZAC1, reducing a
      tumor-suppressor program that normally restrains proliferation.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:30447469
      reference_title: "A Novel Mutation of Aryl Hydrocarbon Receptor Interacting Protein Gene Associated with Familial Isolated Pituitary Adenoma Mediates Tumor Invasion and Growth Hormone Hypersecretion."
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: >-
        the experimental group cells expressed less Sstr2 (a prerequisite for
        the responsiveness to somatostatin analogues) and Zac1 (tumor suppressor
        gene), but more IL-6 and phosphorylated-Stat3 (GH-secretion related).
      explanation: >-
        This directly links pathogenic AIP variation to lower PLAGL1/ZAC1
        expression.
  - target: IL-6/STAT3 activation in AIP-mutant somatotrophs
    description: >-
      AIP-mutant somatotroph cells show increased IL-6 and phosphorylated
      STAT3, linking the AIP-deficient state to a cytokine-signaling program.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:30447469
      reference_title: "A Novel Mutation of Aryl Hydrocarbon Receptor Interacting Protein Gene Associated with Familial Isolated Pituitary Adenoma Mediates Tumor Invasion and Growth Hormone Hypersecretion."
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: >-
        the experimental group cells expressed less Sstr2 (a prerequisite for
        the responsiveness to somatostatin analogues) and Zac1 (tumor suppressor
        gene), but more IL-6 and phosphorylated-Stat3 (GH-secretion related).
      explanation: >-
        This directly links pathogenic AIP variation to increased IL-6 and
        phosphorylated STAT3.
- name: Reduced AIP AHR/HSP90 co-chaperone binding function
  description: >-
    AIP normally acts as a co-chaperone that binds the aryl hydrocarbon
    receptor and HSP90 chaperone machinery. AIP loss reduces this molecular
    binding function and disrupts handling of the latent AHR complex.
  gene:
    preferred_term: AIP
    term:
      id: hgnc:358
      label: AIP
  genes:
  - preferred_term: AHR
    term:
      id: hgnc:348
      label: AHR
  molecular_functions:
  - preferred_term: aryl hydrocarbon receptor binding
    modifier: DECREASED
    term:
      id: GO:0017162
      label: aryl hydrocarbon receptor binding
  - preferred_term: Hsp90 protein binding
    modifier: DECREASED
    term:
      id: GO:0051879
      label: Hsp90 protein binding
  evidence:
  - reference: PMID:16728643
    reference_title: "Pituitary adenoma predisposition caused by germline mutations in the AIP gene."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      AIP acts in cytoplasmic retention of the latent form of the aryl
      hydrocarbon receptor and also has other functions.
    explanation: >-
      This directly supports disruption of AIP-dependent AHR complex handling as
      a component of disease biology.
  - reference: PMID:27080473
    reference_title: "AIP mutations impair AhR signaling in pituitary adenoma patients fibroblasts and in GH3 cells."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: >-
      As 75% of AIP mutations disrupt the physical and/or functional
      interaction with AhR, we postulated that the tumorigenic potential of AIP
      mutations might result from altered AhR signaling.
    explanation: >-
      This supports the AIP-AHR interaction as a mechanistic axis affected by
      pathogenic AIP variants.
  downstream:
  - target: Dysregulated AHR target-gene transcriptional response
    description: >-
      Disruption of AIP-dependent AHR complex handling dysregulates AHR
      target-gene transcriptional responses.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:27080473
      reference_title: "AIP mutations impair AhR signaling in pituitary adenoma patients fibroblasts and in GH3 cells."
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: >-
        This study of human fibroblasts bearing endogenous heterozygous AIP
        mutations and transfected pituitary GH3 cells shows that AIP mutations
        affect the AIP protein level and alter AhR transcriptional activity in
        a gene- and tissue-dependent manner.
      explanation: >-
        This directly links AIP mutation to altered AHR transcriptional
        activity.
- name: Dysregulated AHR target-gene transcriptional response
  description: >-
    AIP-dependent handling of the AHR complex is required for normal
    ligand-responsive AHR target-gene transcription; loss of AIP dysregulates
    this response, including CYP1B1 and AHRR expression after endogenous AHR
    ligand stimulation.
  gene:
    preferred_term: AHR
    term:
      id: hgnc:348
      label: AHR
  biological_processes:
  - preferred_term: AHR-dependent transcriptional response
    modifier: DYSREGULATED
    term:
      id: GO:0006355
      label: regulation of DNA-templated transcription
  - preferred_term: xenobiotic-response signaling
    modifier: DYSREGULATED
    term:
      id: GO:0009410
      label: response to xenobiotic stimulus
  evidence:
  - reference: PMID:27080473
    reference_title: "AIP mutations impair AhR signaling in pituitary adenoma patients fibroblasts and in GH3 cells."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: >-
      Gene expression analyses showed significant modifications in the
      expression of the AhR target genes CYP1B1 and AHRR in AIP-mutated
      fibroblasts, both before and after stimulation with the endogenous AhR
      ligand kynurenine.
    explanation: >-
      This directly supports altered AHR target-gene transcription downstream
      of AIP mutation.
  downstream:
  - target: Altered ligand-dependent growth hormone secretion
    description: >-
      AIP-dependent disruption of AHR signaling affects kynurenine-dependent
      growth hormone secretion in pituitary GH3 cells.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:27080473
      reference_title: "AIP mutations impair AhR signaling in pituitary adenoma patients fibroblasts and in GH3 cells."
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: >-
        Both mutant AIP expression and knockdown of endogenous Aip affected the
        kynurenine-dependent GH secretion of GH3 cells.
      explanation: >-
        This links altered AIP-AHR signaling to a measurable endocrine
        secretion outcome in a pituitary cell model.
- name: Altered ligand-dependent growth hormone secretion
  description: >-
    In pituitary GH3 cells, mutant AIP expression or Aip knockdown changes the
    growth-hormone secretory response to the endogenous AHR ligand kynurenine.
    The direction and causal contribution of this AHR branch to clinical
    somatotroph tumor growth remain unresolved.
  cell_types:
  - preferred_term: somatotroph
    term:
      id: CL:0002312
      label: somatotroph
  genes:
  - preferred_term: AIP
    term:
      id: hgnc:358
      label: AIP
  - preferred_term: AHR
    term:
      id: hgnc:348
      label: AHR
  biological_processes:
  - preferred_term: ligand-dependent growth hormone secretion
    modifier: DYSREGULATED
    term:
      id: GO:0030252
      label: growth hormone secretion
  evidence:
  - reference: PMID:27080473
    reference_title: "AIP mutations impair AhR signaling in pituitary adenoma patients fibroblasts and in GH3 cells."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: >-
      Both mutant AIP expression and knockdown of endogenous Aip affected the
      kynurenine-dependent GH secretion of GH3 cells.
    explanation: >-
      This supports altered ligand-dependent GH secretion as a downstream
      readout of AIP-AHR pathway disruption in a pituitary cell model.
- name: Defective GNAI2/GNAI3-mediated adenylate cyclase restraint
  description: >-
    AIP deficiency impairs GNAI2/GNAI3 proteins that normally inhibit
    adenylate cyclase, decreasing inhibitory control over cAMP synthesis in
    somatotroph cells.
  cell_types:
  - preferred_term: somatotroph
    term:
      id: CL:0002312
      label: somatotroph
  genes:
  - preferred_term: GNAI2
    term:
      id: hgnc:4385
      label: GNAI2
  - preferred_term: GNAI3
    term:
      id: hgnc:4387
      label: GNAI3
  biological_processes:
  - preferred_term: adenylate cyclase-modulating GPCR signaling
    modifier: ABNORMAL
    term:
      id: GO:0007188
      label: adenylate cyclase-modulating G protein-coupled receptor signaling pathway
  evidence:
  - reference: PMID:24662816
    reference_title: "AIP inactivation leads to pituitary tumorigenesis through defective Gαi-cAMP signaling."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: >-
      AIP deficiency leads to elevated cAMP concentrations through defective
      Gαi-2 and Gαi-3 proteins that normally inhibit cAMP synthesis.
    explanation: >-
      This supports increased cAMP signaling as a central consequence of AIP
      deficiency.
  - reference: PMID:24662816
    reference_title: "AIP inactivation leads to pituitary tumorigenesis through defective Gαi-cAMP signaling."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: >-
      This study implies for the first time that a failure to inhibit cAMP
      synthesis through dysfunctional Gαi signaling underlies the development of
      GH-secreting pituitary adenomas in AIP mutation carriers.
    explanation: >-
      This directly links defective Gi-cAMP control to the somatotroph-predominant
      tumor phenotype seen in AIP mutation carriers.
  downstream:
  - target: Increased cAMP/PKA signaling in somatotrophs
    description: >-
      Failure of GNAI2/GNAI3-mediated adenylate cyclase restraint elevates cAMP
      signaling in AIP-deficient somatotrophs.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:24662816
      reference_title: "AIP inactivation leads to pituitary tumorigenesis through defective Gαi-cAMP signaling."
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: >-
        AIP deficiency leads to elevated cAMP concentrations through defective
        Gαi-2 and Gαi-3 proteins that normally inhibit cAMP synthesis.
      explanation: >-
        This directly connects defective GNAI2/GNAI3 inhibition to increased
        cAMP in AIP-deficient cells.
- name: Disrupted AIP-dependent PDE4A cAMP-phosphodiesterase module
  description: >-
    AIP normally participates as a co-chaperone/scaffold in a
    phosphodiesterase module that includes PDE4A isoforms. This module links
    AIP to compartmentalized cAMP control by binding PDE enzymes and modulating
    PDE4A-family cAMP phosphodiesterase activity/localization; loss of AIP
    disrupts that module.
  cell_types:
  - preferred_term: somatotroph
    term:
      id: CL:0002312
      label: somatotroph
  genes:
  - preferred_term: AIP
    term:
      id: hgnc:358
      label: AIP
  - preferred_term: PDE4A
    term:
      id: hgnc:8780
      label: PDE4A
  molecular_functions:
  - preferred_term: AIP binding to phosphodiesterase enzyme
    modifier: DECREASED
    term:
      id: GO:0019899
      label: enzyme binding
  - preferred_term: AIP-PDE4A protein complex binding
    modifier: DYSREGULATED
    term:
      id: GO:0044877
      label: protein-containing complex binding
  biological_processes:
  - preferred_term: AIP-dependent regulation of PDE-mediated cyclic nucleotide catabolism
    modifier: ABNORMAL
    term:
      id: GO:0030805
      label: regulation of cyclic nucleotide catabolic process
  evidence:
  - reference: PMID:28427099
    reference_title: "Role of Phosphodiesterases on the Function of Aryl Hydrocarbon Receptor-Interacting Protein (AIP) in the Pituitary Gland and on the Evaluation of AIP Gene Variants."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: >-
      the well-known interaction between AIP and 2 different isoforms of
      phosphodiesterases (PDEs), PDE2A3 and PDE4A5, is of particular interest
    explanation: >-
      This review establishes the AIP-PDE4A5 (PDE4A4) and AIP-PDE2A3
      interactions as a recognized component of the cAMP-PDE axis disturbed
      in AIP-mutant pituitary disease.
  - reference: PMID:28427099
    reference_title: "Role of Phosphodiesterases on the Function of Aryl Hydrocarbon Receptor-Interacting Protein (AIP) in the Pituitary Gland and on the Evaluation of AIP Gene Variants."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: >-
      While the interaction with over-expressed AIP does not seem to affect
      PDE2A3 function, the reported effect on PDE4A5 is, in contrast, reduced
      enzymatic activity.
    explanation: >-
      This supports the more specific interpretation that the AIP-PDE4A module
      modulates PDE4A-family enzymatic function rather than representing a
      generic protein-protein contact only.
  downstream:
  - target: Reduced PDE4A-mediated cAMP catabolism
    description: >-
      Loss of the AIP-dependent PDE4A module reduces the PDE4A4/PDE4A8
      compensation that normally degrades cAMP in somatotroph tumors.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:29729370
      reference_title: "Reduced protein expression of the phosphodiesterases PDE4A4 and PDE4A8 in AIP mutation positive somatotroph adenomas."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        we suggest that lack of AIP hinders the upregulation of PDE4A8 and
        PDE4A4 protein seen in sporadic somatotrophinomas
      explanation: >-
        This directly attributes failure of PDE4A4/PDE4A8 compensation to AIP
        loss.
- name: Reduced PDE4A-mediated cAMP catabolism
  conforms_to: somatotroph_camp_pka_overactivation#Increased somatotroph cAMP availability
  description: >-
    AIP-mutant somatotroph tumors show lower PDE4A4/PDE4A8 protein expression,
    reducing cAMP degradation and contributing to a cAMP-PDE pathway
    disturbance.
  cell_types:
  - preferred_term: somatotroph
    term:
      id: CL:0002312
      label: somatotroph
  genes:
  - preferred_term: PDE4A
    term:
      id: hgnc:8780
      label: PDE4A
  molecular_functions:
  - preferred_term: PDE4A cAMP-specific phosphodiesterase activity
    modifier: DECREASED
    term:
      id: GO:0004115
      label: 3',5'-cyclic-AMP phosphodiesterase activity
  biological_processes:
  - preferred_term: PDE4A-mediated cAMP catabolism
    modifier: DECREASED
    term:
      id: GO:0006198
      label: cAMP catabolic process
  evidence:
  - reference: PMID:29729370
    reference_title: "Reduced protein expression of the phosphodiesterases PDE4A4 and PDE4A8 in AIP mutation positive somatotroph adenomas."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Confocal immunofluorescence analysis showed that both PDE4A8 and PDE4A4
      had lower expression in AIP-mutated somatotropinoma samples compared to
      sporadic GH-secreting tumours
    explanation: >-
      This directly supports reduced PDE4A4 and PDE4A8 protein expression in
      AIP-mutant somatotropinomas relative to sporadic GH-secreting tumors.
  - reference: PMID:29729370
    reference_title: "Reduced protein expression of the phosphodiesterases PDE4A4 and PDE4A8 in AIP mutation positive somatotroph adenomas."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      These data point to a unique disturbance of the cAMP-PDE pathway in
      AIP-mutation positive adenomas, which may help to explain their
      well-described poor response to somatostatin analogues.
    explanation: >-
      This explicitly links the cAMP-PDE pathway disturbance in AIP-mutant
      tumors to their somatostatin-analog resistance.
  downstream:
  - target: Increased cAMP/PKA signaling in somatotrophs
    description: >-
      Reduced PDE4A4/PDE4A8 expression limits cAMP degradation, feeding into
      elevated cAMP/PKA signaling.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:29729370
      reference_title: "Reduced protein expression of the phosphodiesterases PDE4A4 and PDE4A8 in AIP mutation positive somatotroph adenomas."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        These data point to a unique disturbance of the cAMP-PDE pathway in
        AIP-mutation positive adenomas, which may help to explain their
        well-described poor response to somatostatin analogues.
      explanation: >-
        The cAMP-PDE disturbance supports a route from reduced PDE4A-mediated
        catabolism to elevated cAMP signaling.
- name: Increased cAMP/PKA signaling in somatotrophs
  conforms_to: somatotroph_camp_pka_overactivation#Increased cAMP/PKA signaling in somatotrophs
  description: >-
    Convergent GNAI2/GNAI3 and PDE4A defects leave cAMP/PKA signaling elevated
    in AIP-deficient somatotrophs, promoting GH-secreting pituitary adenoma
    biology.
  cell_types:
  - preferred_term: somatotroph
    term:
      id: CL:0002312
      label: somatotroph
  biological_processes:
  - preferred_term: cAMP-mediated signaling
    modifier: INCREASED
    term:
      id: GO:0141156
      label: cAMP/PKA signal transduction
  evidence:
  - reference: PMID:24662816
    reference_title: "AIP inactivation leads to pituitary tumorigenesis through defective Gαi-cAMP signaling."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: >-
      This study implies for the first time that a failure to inhibit cAMP
      synthesis through dysfunctional Gαi signaling underlies the development of
      GH-secreting pituitary adenomas in AIP mutation carriers.
    explanation: >-
      This supports elevated cAMP signaling as a proximal driver of
      GH-secreting pituitary adenoma development in AIP mutation carriers.
  downstream:
  - target: Pituitary macroadenoma
    description: >-
      Elevated cAMP/PKA signaling contributes to development of large,
      GH-secreting pituitary adenomas in AIP mutation carriers.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:24662816
      reference_title: "AIP inactivation leads to pituitary tumorigenesis through defective Gαi-cAMP signaling."
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: >-
        This study implies for the first time that a failure to inhibit cAMP
        synthesis through dysfunctional Gαi signaling underlies the development of
        GH-secreting pituitary adenomas in AIP mutation carriers.
      explanation: >-
        This supports defective cAMP restraint as a route to GH-secreting
        adenoma development.
  - target: Growth hormone excess
    description: >-
      The AIP-deficient cAMP program favors a GH-secreting somatotroph tumor
      phenotype.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:23310926
      reference_title: "Familial isolated pituitary adenomas: an emerging clinical entity."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        AIP mutations cause a low penetrance autosomal dominant disease with often
        a distinct phenotype characterized by young-onset, aggressive, large GH,
        mixed GH and PRL or PRL-secreting adenomas.
      explanation: >-
        This human clinical summary supports GH-secreting disease as a dominant
        phenotype of AIP-related pituitary adenoma predisposition.
  - target: Pituitary adenoma
    description: >-
      Defective cAMP restraint in AIP mutation carriers contributes to
      GH-secreting pituitary adenoma development within the AIP-related
      predisposition spectrum.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:24662816
      reference_title: "AIP inactivation leads to pituitary tumorigenesis through defective Gαi-cAMP signaling."
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: >-
        This study implies for the first time that a failure to inhibit cAMP
        synthesis through dysfunctional Gαi signaling underlies the development of
        GH-secreting pituitary adenomas in AIP mutation carriers.
      explanation: >-
        This supports defective cAMP restraint as a mechanistic route to
        pituitary adenoma development in AIP mutation carriers.
  - target: Hyperprolactinemia
    description: >-
      AIP-related adenomas include mixed GH/PRL-secreting and PRL-secreting
      tumors; the specific mechanistic bridge from the somatotroph cAMP branch
      to prolactin excess remains unresolved.
    causal_link_type: UNKNOWN
    evidence:
    - reference: PMID:23310926
      reference_title: "Familial isolated pituitary adenomas: an emerging clinical entity."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        AIP mutations cause a low penetrance autosomal dominant disease with often
        a distinct phenotype characterized by young-onset, aggressive, large GH,
        mixed GH and PRL or PRL-secreting adenomas.
      explanation: >-
        This review supports prolactin-secreting adenomas within the AIP-related
        tumor spectrum, while leaving the exact signaling route unresolved.
- name: Reduced SSTR2 expression in AIP-mutant somatotrophs
  description: >-
    Pathogenic AIP variants reduce SSTR2 expression in somatotroph cells,
    weakening receptor-level sensitivity to first-generation somatostatin
    analogs.
  cell_types:
  - preferred_term: somatotroph
    term:
      id: CL:0002312
      label: somatotroph
  genes:
  - preferred_term: SSTR2
    term:
      id: hgnc:11331
      label: SSTR2
  evidence:
  - reference: PMID:30447469
    reference_title: "A Novel Mutation of Aryl Hydrocarbon Receptor Interacting Protein Gene Associated with Familial Isolated Pituitary Adenoma Mediates Tumor Invasion and Growth Hormone Hypersecretion."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: >-
      the experimental group cells expressed less Sstr2 (a prerequisite for
      the responsiveness to somatostatin analogues) and Zac1 (tumor suppressor
      gene), but more IL-6 and phosphorylated-Stat3 (GH-secretion related).
    explanation: >-
      This directly supports reduced SSTR2 expression as a discrete downstream
      effect of pathogenic AIP variation.
  - reference: PMID:22659247
    reference_title: "Somatostatin analogs modulate AIP in somatotroph adenomas: the role of the ZAC1 pathway."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Somatotroph adenomas harboring aryl hydrocarbon receptor interacting
      protein (AIP) mutations respond less well to somatostatin analogs
    explanation: >-
      This human clinical observation supports the treatment-response relevance
      of SSTR2-linked AIP-mutant tumor biology.
- name: Reduced PLAGL1/ZAC1 tumor-suppressor signaling
  description: >-
    Pathogenic AIP variants reduce PLAGL1/ZAC1 expression in somatotroph cells,
    weakening a tumor-suppressor program that normally restrains growth.
  cell_types:
  - preferred_term: somatotroph
    term:
      id: CL:0002312
      label: somatotroph
  genes:
  - preferred_term: PLAGL1 (ZAC1)
    term:
      id: hgnc:9046
      label: PLAGL1
  evidence:
  - reference: PMID:30447469
    reference_title: "A Novel Mutation of Aryl Hydrocarbon Receptor Interacting Protein Gene Associated with Familial Isolated Pituitary Adenoma Mediates Tumor Invasion and Growth Hormone Hypersecretion."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: >-
      the experimental group cells expressed less Sstr2 (a prerequisite for
      the responsiveness to somatostatin analogues) and Zac1 (tumor suppressor
      gene), but more IL-6 and phosphorylated-Stat3 (GH-secretion related).
    explanation: >-
      This directly supports reduced PLAGL1/ZAC1 expression as a discrete
      downstream effect of pathogenic AIP variation.
  downstream:
  - target: Increased somatotroph proliferation and invasiveness
    description: >-
      Loss of the ZAC1 tumor-suppressor program contributes to increased
      proliferation and invasion in AIP-mutant somatotroph cells.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:30447469
      reference_title: "A Novel Mutation of Aryl Hydrocarbon Receptor Interacting Protein Gene Associated with Familial Isolated Pituitary Adenoma Mediates Tumor Invasion and Growth Hormone Hypersecretion."
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: >-
        The novel AIP mutation c.512C>T (p.T171I) is a pathogenic variant that
        promoted cell proliferation, invasiveness, and GH secretion through
        regulation of Sstr2, Zac1, and IL-6/phosphorylated-Stat3 expression.
      explanation: >-
        This links the SSTR2/ZAC1/IL-6/phospho-STAT3 expression program to
        proliferation and invasion.
- name: IL-6/STAT3 activation in AIP-mutant somatotrophs
  description: >-
    AIP-mutant somatotroph cells show increased IL-6 and phosphorylated STAT3,
    a cytokine-signaling branch associated with GH secretion, proliferation,
    and invasiveness.
  cell_types:
  - preferred_term: somatotroph
    term:
      id: CL:0002312
      label: somatotroph
  genes:
  - preferred_term: IL6
    term:
      id: hgnc:6018
      label: IL6
  - preferred_term: STAT3
    term:
      id: hgnc:11364
      label: STAT3
  biological_processes:
  - preferred_term: IL-6/STAT3 signaling
    modifier: INCREASED
    term:
      id: GO:0070102
      label: interleukin-6-mediated signaling pathway
  evidence:
  - reference: PMID:30447469
    reference_title: "A Novel Mutation of Aryl Hydrocarbon Receptor Interacting Protein Gene Associated with Familial Isolated Pituitary Adenoma Mediates Tumor Invasion and Growth Hormone Hypersecretion."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: >-
      the experimental group cells expressed less Sstr2 (a prerequisite for
      the responsiveness to somatostatin analogues) and Zac1 (tumor suppressor
      gene), but more IL-6 and phosphorylated-Stat3 (GH-secretion related).
    explanation: >-
      This in vitro study with a pathogenic AIP variant directly demonstrates
      increased IL-6 and phospho-STAT3 in AIP-mutant somatotroph cells.
  - reference: PMID:30447469
    reference_title: "A Novel Mutation of Aryl Hydrocarbon Receptor Interacting Protein Gene Associated with Familial Isolated Pituitary Adenoma Mediates Tumor Invasion and Growth Hormone Hypersecretion."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: >-
      The novel AIP mutation c.512C>T (p.T171I) is a pathogenic variant that
      promoted cell proliferation, invasiveness, and GH secretion through
      regulation of Sstr2, Zac1, and IL-6/phosphorylated-Stat3 expression.
    explanation: >-
      This identifies IL-6/phospho-STAT3 regulation as part of the mechanistic
      route by which an AIP loss-of-function variant promotes proliferation,
      invasion, and GH secretion.
  downstream:
  - target: Increased somatotroph proliferation and invasiveness
    description: >-
      IL-6/phospho-STAT3 activation contributes to the proliferative and
      invasive AIP-mutant somatotroph phenotype.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:30447469
      reference_title: "A Novel Mutation of Aryl Hydrocarbon Receptor Interacting Protein Gene Associated with Familial Isolated Pituitary Adenoma Mediates Tumor Invasion and Growth Hormone Hypersecretion."
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: >-
        The novel AIP mutation c.512C>T (p.T171I) is a pathogenic variant that
        promoted cell proliferation, invasiveness, and GH secretion through
        regulation of Sstr2, Zac1, and IL-6/phosphorylated-Stat3 expression.
      explanation: >-
        This links IL-6/phospho-STAT3 regulation to proliferation and invasion
        in AIP-mutant somatotroph cells.
  - target: Growth hormone excess
    description: >-
      IL-6/phospho-STAT3 activation is associated with GH secretion in
      AIP-mutant somatotroph cells.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:30447469
      reference_title: "A Novel Mutation of Aryl Hydrocarbon Receptor Interacting Protein Gene Associated with Familial Isolated Pituitary Adenoma Mediates Tumor Invasion and Growth Hormone Hypersecretion."
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: >-
        The novel AIP mutation c.512C>T (p.T171I) is a pathogenic variant that
        promoted cell proliferation, invasiveness, and GH secretion through
        regulation of Sstr2, Zac1, and IL-6/phosphorylated-Stat3 expression.
      explanation: >-
        This supports a causal link from the IL-6/phospho-STAT3 program to GH
        secretion.
- name: Increased somatotroph proliferation and invasiveness
  description: >-
    The AIP-mutant SSTR2/ZAC1/IL-6/STAT3 expression program promotes
    somatotroph proliferation and invasion, contributing to the aggressive,
    large adenoma phenotype.
  cell_types:
  - preferred_term: somatotroph
    term:
      id: CL:0002312
      label: somatotroph
  biological_processes:
  - preferred_term: somatotroph proliferation
    modifier: INCREASED
    term:
      id: GO:0008283
      label: cell population proliferation
  evidence:
  - reference: PMID:30447469
    reference_title: "A Novel Mutation of Aryl Hydrocarbon Receptor Interacting Protein Gene Associated with Familial Isolated Pituitary Adenoma Mediates Tumor Invasion and Growth Hormone Hypersecretion."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: >-
      The novel AIP mutation c.512C>T (p.T171I) is a pathogenic variant that
      promoted cell proliferation, invasiveness, and GH secretion through
      regulation of Sstr2, Zac1, and IL-6/phosphorylated-Stat3 expression.
    explanation: >-
      This directly supports increased proliferation and invasion downstream of
      the AIP-mutant expression program.
  downstream:
  - target: Pituitary macroadenoma
    description: >-
      Increased somatotroph proliferation and invasion contribute to large,
      aggressive pituitary adenomas.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:23310926
      reference_title: "Familial isolated pituitary adenomas: an emerging clinical entity."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        AIP mutations cause a low penetrance autosomal dominant disease with often
        a distinct phenotype characterized by young-onset, aggressive, large GH,
        mixed GH and PRL or PRL-secreting adenomas.
      explanation: >-
        This review supports large aggressive adenomas as a characteristic
        clinical outcome of AIP-related disease.
  - target: Headache
    description: >-
      Large AIP-associated pituitary macroadenomas can cause headache through
      sellar mass effect.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:22720333
      reference_title: "AIP Familial Isolated Pituitary Adenomas."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        Clinical findings result from excess hormone secretion, lack of hormone
        secretion, and/or mass effects (e.g., headaches, visual field loss).
      explanation: >-
        GeneReviews supports headache as a mass-effect manifestation of
        AIP-associated pituitary tumors.
  - target: Visual field defect
    description: >-
      Suprasellar extension of large AIP-associated pituitary tumors can cause
      visual field loss by optic apparatus compression.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:22720333
      reference_title: "AIP Familial Isolated Pituitary Adenomas."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        Clinical findings result from excess hormone secretion, lack of hormone
        secretion, and/or mass effects (e.g., headaches, visual field loss).
      explanation: >-
        GeneReviews supports visual field loss as a mass-effect manifestation
        of large AIP-associated pituitary tumors.
phenotypes:
- category: Neoplastic
  name: Pituitary adenoma
  diagnostic: true
  description: >-
    The defining neoplastic manifestation is pituitary adenoma predisposition,
    often recognized through familial clustering or young-onset apparently
    sporadic disease.
  phenotype_term:
    preferred_term: Pituitary adenoma
    term:
      id: HP:0002893
      label: Pituitary adenoma
  evidence:
  - reference: PMID:17360484
    reference_title: "Molecular diagnosis of pituitary adenoma predisposition caused by aryl hydrocarbon receptor-interacting protein gene mutations."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Germ-line mutations in the aryl hydrocarbon receptor-interacting protein
      (AIP) gene cause pituitary adenoma predisposition (PAP).
    explanation: >-
      This validates pituitary adenoma predisposition as the core clinical
      manifestation of germline AIP disease.
- category: Neoplastic
  name: Pituitary macroadenoma
  description: >-
    AIP-related tumors are typically large pituitary adenomas at diagnosis,
    particularly in childhood, adolescence, and young adulthood.
  phenotype_term:
    preferred_term: Pituitary macroadenoma
    term:
      id: HP:0025693
      label: Pituitary macroadenoma
  sequelae:
  - target: Headache
    description: >-
      Large pituitary macroadenomas can cause headache through local sellar
      mass effect.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:22720333
      reference_title: "AIP Familial Isolated Pituitary Adenomas."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        Clinical findings result from excess hormone secretion, lack of hormone
        secretion, and/or mass effects (e.g., headaches, visual field loss).
      explanation: >-
        GeneReviews supports headache as a mass-effect consequence of large
        AIP-associated pituitary tumors.
  - target: Visual field defect
    description: >-
      Suprasellar macroadenoma extension can compress the optic apparatus and
      cause visual field loss.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:22720333
      reference_title: "AIP Familial Isolated Pituitary Adenomas."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        Clinical findings result from excess hormone secretion, lack of hormone
        secretion, and/or mass effects (e.g., headaches, visual field loss).
      explanation: >-
        GeneReviews supports visual field loss as a mass-effect consequence of
        large AIP-associated pituitary tumors.
  evidence:
  - reference: PMID:17893250
    reference_title: "The clinical, pathological, and genetic features of familial isolated pituitary adenomas."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Patients with FIPA are significantly younger at diagnosis and have
      significantly larger pituitary adenomas than matched sporadic pituitary
      adenoma counterparts.
    explanation: >-
      This supports the tendency toward larger pituitary tumors in the FIPA
      setting that includes AIP-related disease.
  - reference: PMID:21753072
    reference_title: "High prevalence of AIP gene mutations following focused screening in young patients with sporadic pituitary macroadenomas."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Germline AIPmut occur in 11.7% of patients <30 years with sporadic
      pituitary macroadenomas and in 20.5% of pediatric patients.
    explanation: >-
      This focused young-onset cohort supports macroadenoma as a common
      presenting tumor form in AIP mutation carriers.
- category: Endocrine
  name: Growth hormone excess
  description: >-
    Somatotroph-predominant tumors commonly cause biochemical growth hormone
    excess with gigantism in pediatric-onset disease or acromegaly after
    epiphyseal fusion.
  phenotype_term:
    preferred_term: Growth hormone excess
    term:
      id: HP:0000845
      label: Elevated circulating growth hormone concentration
  evidence:
  - reference: PMID:23310926
    reference_title: "Familial isolated pituitary adenomas: an emerging clinical entity."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      AIP mutations cause a low penetrance autosomal dominant disease with often
      a distinct phenotype characterized by young-onset, aggressive, large GH,
      mixed GH and PRL or PRL-secreting adenomas.
    explanation: >-
      This review supports growth hormone excess as a dominant endocrine feature
      of AIP-related pituitary adenoma predisposition.
- category: Endocrine
  name: Hyperprolactinemia
  description: >-
    Mixed GH/PRL-secreting adenomas and pure prolactinomas are part of the
    AIP-related tumor spectrum, making prolactin excess a recurrent endocrine
    feature.
  phenotype_term:
    preferred_term: Increased circulating prolactin concentration
    term:
      id: HP:0000870
      label: Increased circulating prolactin concentration
  evidence:
  - reference: PMID:23310926
    reference_title: "Familial isolated pituitary adenomas: an emerging clinical entity."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      AIP mutations cause a low penetrance autosomal dominant disease with often
      a distinct phenotype characterized by young-onset, aggressive, large GH,
      mixed GH and PRL or PRL-secreting adenomas.
    explanation: >-
      This review supports recurrent prolactin excess within the AIP-related
      adenoma spectrum.
- category: Neurological
  name: Headache
  description: >-
    Large tumors can present with headache due to local sellar mass effect.
  phenotype_term:
    preferred_term: Headache
    term:
      id: HP:0002315
      label: Headache
  evidence:
  - reference: PMID:22720333
    reference_title: "AIP Familial Isolated Pituitary Adenomas."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Clinical findings result from excess hormone secretion, lack of hormone
      secretion, and/or mass effects (e.g., headaches, visual field loss).
    explanation: >-
      This GeneReviews summary supports headache as a common mass-effect
      manifestation of AIP-associated pituitary tumors.
- category: Ophthalmologic
  name: Visual field defect
  description: >-
    Suprasellar extension and optic chiasm compression can cause visual field
    loss in large pituitary macroadenomas.
  phenotype_term:
    preferred_term: Visual field defect
    term:
      id: HP:0001123
      label: Visual field defect
  evidence:
  - reference: PMID:22720333
    reference_title: "AIP Familial Isolated Pituitary Adenomas."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Clinical findings result from excess hormone secretion, lack of hormone
      secretion, and/or mass effects (e.g., headaches, visual field loss).
    explanation: >-
      This GeneReviews summary supports visual field loss as a mass-effect
      manifestation of large AIP-associated pituitary tumors.
discussions:
- discussion_id: gap_aip_ahr_branch_tumor_growth_causality
  prompt: >-
    Does altered AIP-AHR transcriptional signaling directly promote somatotroph
    tumor growth or invasiveness in human AIP-mutant pituitary adenomas, beyond
    the demonstrated cell-model effects on AHR target genes and
    ligand-dependent growth hormone secretion?
  kind: KNOWLEDGE_GAP
  status: OPEN
  attaches_to:
  - pathophysiology#Reduced AIP AHR/HSP90 co-chaperone binding function
  - pathophysiology#Dysregulated AHR target-gene transcriptional response
  - pathophysiology#Altered ligand-dependent growth hormone secretion
  - phenotype#Growth hormone excess
  rationale: >-
    The AIP-AHR branch now has a supported immediate outcome: altered AHR
    target-gene transcription and altered kynurenine-dependent GH secretion in
    GH3 cells. What remains unresolved is whether that branch is a causal driver
    of the human macroadenoma growth and invasiveness phenotype, rather than a
    measurable molecular/endocrine readout of AIP loss.
  evidence:
  - reference: PMID:27080473
    reference_title: "AIP mutations impair AhR signaling in pituitary adenoma patients fibroblasts and in GH3 cells."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: >-
      Germline mutations in the aryl hydrocarbon receptor-interacting protein
      (AIP) gene predispose humans to pituitary adenomas through unknown
      molecular mechanisms.
    explanation: >-
      This frames the AIP-AHR pathway as a mechanistic hypothesis while leaving
      the causal bridge to human pituitary tumor growth unresolved.
diagnosis:
- name: Clinical selection for AIP-focused evaluation
  diagnosis_term:
    preferred_term: clinical assessment
    term:
      id: MAXO:0000487
      label: clinical assessment
  description: >-
    Young-onset pituitary macroadenoma, pediatric somatotropinoma, or a FIPA
    context should trigger targeted evaluation for germline AIP-related disease.
  results: >-
    Early age at diagnosis and macroadenoma presentation support directed AIP
    testing and family-based assessment.
  evidence:
  - reference: PMID:21753072
    reference_title: "High prevalence of AIP gene mutations following focused screening in young patients with sporadic pituitary macroadenomas."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Germline AIPmut occur in 11.7% of patients <30 years with sporadic
      pituitary macroadenomas and in 20.5% of pediatric patients.
    explanation: >-
      This prospective study supports targeted AIP evaluation in young and
      pediatric macroadenoma patients.
  - reference: PMID:21753072
    reference_title: "High prevalence of AIP gene mutations following focused screening in young patients with sporadic pituitary macroadenomas."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      AIPmut mutation testing in this population should be considered in order
      to optimize clinical genetic investigation and management.
    explanation: >-
      This explicitly supports using the young-onset macroadenoma phenotype to
      guide diagnostic testing strategy.
- name: AIP immunohistochemistry-guided prescreening
  diagnosis_term:
    preferred_term: clinical assessment
    term:
      id: MAXO:0000487
      label: clinical assessment
  description: >-
    AIP immunohistochemistry on tumor tissue can function as a prescreening
    step before germline testing in suspected AIP-related pituitary adenoma
    predisposition.
  results: >-
    Low or negative AIP immunostaining supports follow-up genetic counseling
    and AIP mutation analysis.
  evidence:
  - reference: PMID:17360484
    reference_title: "Molecular diagnosis of pituitary adenoma predisposition caused by aryl hydrocarbon receptor-interacting protein gene mutations."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      AIP IHC staining levels proved to be a useful predictor of AIP status,
      with 75% sensitivity and 95% specificity for germ-line mutations.
    explanation: >-
      This directly supports AIP immunohistochemistry as a prescreening test in
      suspected AIP-related disease.
  - reference: PMID:17360484
    reference_title: "Molecular diagnosis of pituitary adenoma predisposition caused by aryl hydrocarbon receptor-interacting protein gene mutations."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      AIP IHC, followed by genetic counseling and possible AIP mutation
      analysis in IHC-negative cases, a procedure similar to the diagnostics of
      the Lynch syndrome, appears feasible in identification of PAP.
    explanation: >-
      This supports an IHC-to-genetic-testing diagnostic pathway for pituitary
      adenoma predisposition.
- name: AIP molecular genetic testing
  diagnosis_term:
    preferred_term: molecular genetic testing
    term:
      id: MAXO:0000533
      label: molecular genetic testing
    qualifiers:
    - predicate:
        preferred_term: has participant
        term:
          id: RO:0000057
          label: has participant
      value:
        preferred_term: AIP
        term:
          id: hgnc:358
          label: AIP
  description: >-
    Germline AIP testing confirms the molecular diagnosis in a proband with a
    pituitary neuroendocrine tumor and supports cascade testing in relatives.
  results: >-
    Identification of a heterozygous germline pathogenic AIP variant
    establishes the diagnosis.
  evidence:
  - reference: PMID:22720333
    reference_title: "AIP Familial Isolated Pituitary Adenomas."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The diagnosis of AIP-FIPA is established in a proband with a PitNET by
      identification of a heterozygous germline pathogenic variant in AIP by
      molecular genetic testing.
    explanation: >-
      This directly supports germline AIP testing as the confirmatory molecular
      diagnostic step.
genetic:
- name: AIP
  gene_term:
    preferred_term: AIP
    term:
      id: hgnc:358
      label: AIP
  association: >-
    Germline loss-of-function predisposition with somatic second-hit
    tumor-suppressor inactivation
  relationship_type: SUSCEPTIBILITY
  variant_origin: GERMLINE_AND_SOMATIC
  inheritance:
  - name: Autosomal dominant
    evidence:
    - reference: PMID:23310926
      reference_title: "Familial isolated pituitary adenomas: an emerging clinical entity."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        AIP mutations cause a low penetrance autosomal dominant disease with often
        a distinct phenotype characterized by young-onset, aggressive, large GH,
        mixed GH and PRL or PRL-secreting adenomas.
      explanation: >-
        This review directly supports autosomal dominant inheritance for
        AIP-related pituitary adenoma predisposition.
  notes: >-
    AIP encodes an aryl hydrocarbon receptor-interacting HSP90 co-chaperone and
    functions as a pituitary tumor suppressor gene in this syndrome. Germline
    pathogenic variants account for a substantial molecular subset of FIPA and
    are enriched among young patients with apparently sporadic pituitary
    macroadenomas.
  evidence:
  - reference: PMID:16728643
    reference_title: "Pituitary adenoma predisposition caused by germline mutations in the AIP gene."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Combining chip-based technologies with genealogy data, we identified
      germline mutations in the aryl hydrocarbon receptor interacting protein
      (AIP) gene in individuals with pituitary adenoma predisposition (PAP).
    explanation: >-
      This discovery study establishes germline AIP loss-of-function as the core
      causal genetic lesion.
  - reference: PMID:23310926
    reference_title: "Familial isolated pituitary adenomas: an emerging clinical entity."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      identification of a mutation in this gene in 20% of FIPA families
    explanation: >-
      This review supports AIP as a major molecular contributor within FIPA and
      early-onset simplex somatotroph adenoma.
treatments:
- name: Transsphenoidal surgery and multimodal local control
  description: >-
    Large AIP-associated somatotropinomas are usually treated with
    transsphenoidal surgery, with adjuvant medical therapy and radiotherapy
    considered for residual or invasive disease.
  treatment_term:
    preferred_term: surgical procedure
    term:
      id: MAXO:0000004
      label: surgical procedure
  target_phenotypes:
  - preferred_term: Pituitary macroadenoma
    term:
      id: HP:0025693
      label: Pituitary macroadenoma
  - preferred_term: Growth hormone excess
    term:
      id: HP:0000845
      label: Elevated circulating growth hormone concentration
  - preferred_term: Headache
    term:
      id: HP:0002315
      label: Headache
  - preferred_term: Visual field defect
    term:
      id: HP:0001123
      label: Visual field defect
  target_mechanisms:
  - target: Increased somatotroph proliferation and invasiveness
    treatment_effect: MODULATES
    description: >-
      Transsphenoidal resection removes tumor tissue produced by the
      proliferative, invasive somatotroph clone and reduces mass effect.
  evidence:
  - reference: PMID:22720333
    reference_title: "AIP Familial Isolated Pituitary Adenomas."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Large somatotropinomas are treated with transsphenoidal surgery, medical
      therapy, and/or radiotherapy.
    explanation: >-
      This supports surgery as the central local treatment modality for large
      AIP-associated somatotropinomas, with multimodal escalation as needed.
- name: First-generation somatostatin analog therapy with reduced response
  description: >-
    AIP-mutant somatotroph tumors frequently respond less well to
    first-generation somatostatin receptor ligands such as octreotide or
    lanreotide, often necessitating alternative or combination therapy.
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
  target_phenotypes:
  - preferred_term: Growth hormone excess
    term:
      id: HP:0000845
      label: Elevated circulating growth hormone concentration
  target_mechanisms:
  - target: Reduced SSTR2 expression in AIP-mutant somatotrophs
    treatment_effect: MODULATES
    description: >-
      First-generation somatostatin analog response depends on SSTR2; reduced
      SSTR2 expression explains the diminished response in AIP-mutant tumors.
  - target: Reduced PDE4A-mediated cAMP catabolism
    treatment_effect: MODULATES
    description: >-
      The AIP-mutant cAMP-PDE disturbance may contribute to poor
      somatostatin-analog response.
  evidence:
  - reference: PMID:22659247
    reference_title: "Somatostatin analogs modulate AIP in somatotroph adenomas: the role of the ZAC1 pathway."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Somatotroph adenomas harboring aryl hydrocarbon receptor interacting
      protein (AIP) mutations respond less well to somatostatin analogs
    explanation: >-
      This directly supports reduced effectiveness of first-generation
      somatostatin analog treatment in AIP-mutant somatotroph tumors.
  - reference: PMID:29953972
    reference_title: "Resistant Paediatric Somatotropinomas due to AIP Mutations: Role of Pegvisomant."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      AIP mutations are found in 20-25% cases and cause aggressive
      somatotropinomas, often resistant to somatostatin analogues.
    explanation: >-
      This pediatric clinical report reinforces somatostatin analogue
      resistance as a management hallmark of AIP-associated somatotropinomas.
- name: Dopamine agonist and pegvisomant escalation for resistant disease
  description: >-
    Mixed GH/PRL tumors or resistant somatotropinomas may require dopamine
    agonists and GH receptor antagonist therapy as part of multimodal disease
    control.
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
  target_phenotypes:
  - preferred_term: Growth hormone excess
    term:
      id: HP:0000845
      label: Elevated circulating growth hormone concentration
  - preferred_term: Increased circulating prolactin concentration
    term:
      id: HP:0000870
      label: Increased circulating prolactin concentration
  evidence:
  - reference: PMID:22720333
    reference_title: "AIP Familial Isolated Pituitary Adenomas."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      GH receptor antagonists, and dopamine agonists), surgery, and/or
      radiotherapy.
    explanation: >-
      This GeneReviews summary supports dopamine agonists and GH receptor
      antagonists within standard multimodal treatment of GH-producing tumors.
  - reference: PMID:29953972
    reference_title: "Resistant Paediatric Somatotropinomas due to AIP Mutations: Role of Pegvisomant."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      They were initially treated with a long-acting somatostatin analogue
      (octreotide LAR 30 mg/month) and cabergoline as a dopamine agonist, with
      the later addition of pegvisomant titrated up to 20 mg/day and with
      radiotherapy for long-term control.
    explanation: >-
      This pediatric AIP-mutant cohort supports escalation to cabergoline and
      pegvisomant in resistant disease.
- name: Radiotherapy for residual or recurrent tumor control
  description: >-
    Radiotherapy remains an accepted adjunct for residual, recurrent, or
    inoperable AIP-associated pituitary tumors when surgery and medical therapy
    are insufficient.
  treatment_term:
    preferred_term: radiation therapy
    term:
      id: MAXO:0000014
      label: radiation therapy
  target_phenotypes:
  - preferred_term: Pituitary macroadenoma
    term:
      id: HP:0025693
      label: Pituitary macroadenoma
  target_mechanisms:
  - target: Increased somatotroph proliferation and invasiveness
    treatment_effect: INHIBITS
    description: >-
      Radiotherapy is used for residual, recurrent, or inoperable tumor control
      when proliferative tumor tissue remains after surgery and medical therapy.
  evidence:
  - reference: PMID:29953972
    reference_title: "Resistant Paediatric Somatotropinomas due to AIP Mutations: Role of Pegvisomant."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      They were initially treated with a long-acting somatostatin analogue
      (octreotide LAR 30 mg/month) and cabergoline as a dopamine agonist, with
      the later addition of pegvisomant titrated up to 20 mg/day and with
      radiotherapy for long-term control.
    explanation: >-
      This supports radiotherapy as part of multimodal long-term control in
      resistant AIP-mutant somatotropinomas.
references:
- reference: PMID:22720333
  title: "AIP Familial Isolated Pituitary Adenomas."
  tags:
  - GeneReviews
  findings: []

📚

References & Deep Research

References

PMID:22720333

AIP Familial Isolated Pituitary Adenomas.

No top-level findings curated for this source.

Deep Research

Asta ▸

Asta Literature Retrieval: Pathophysiology and clinical mechanisms of AIP-related pituitary adenoma predisposition. Core disease mechanisms, mol...

Asta Scientific Corpus Retrieval 20 citations 2026-04-22T16:59:32.068132

Asta Literature Retrieval: Pathophysiology and clinical mechanisms of AIP-related pituitary adenoma predisposition. Core disease mechanisms, mol...

This report is retrieval-only and is generated directly from Asta results.

Papers retrieved: 20
Snippets retrieved: 20

Relevant Papers

[1] AIP mutations in Brazilian patients with sporadic pituitary adenomas: a single-center evaluation

Authors: P. B. Araújo, L. Kasuki, Carlos Henrique de Azeredo Lima, L. Ogino, A. Camacho et al.
Year: 2017
Venue: Endocrine Connections
URL: https://www.semanticscholar.org/paper/e16e8321121c727ca387d8f7b4e5ca239d95e542
DOI: 10.1530/EC-17-0237
PMID: 29074612
PMCID: 5704447
Citations: 12
Influential citations: 1
Summary: The study identified two mutations exclusively found in Brazilians and also shows, for the first time, loss of heterozygosity in tumor DNA from an acromegaly patient harboring the A299V AIPmut.
Evidence snippets:
Snippet 1 (score: 0.601) > Although most pituitary adenomas occur sporadically, with only 5% of all cases being related to inherited syndromes (1), the mechanisms underlying pituitary tumorigenesis in a non-familial setting are poorly understood. Somatic mutations and other genetic and/or epigenetic abnormalities have been related to SPA, but a minor subgroup of these adenomas can have a germline mutation in a predisposing gene with no known familial history of pituitary adenoma (2). Germline aryl hydrocarbon receptor-interacting protein (AIP) gene mutations (AIPmut) were first described by Vierimaa and coworkers in 2006 (3). This study has found AIPmut in seemingly sporadic acromegaly patients and in familial isolated pituitary adenomas (FIPA) (3), which is characterized by the presence of pituitary adenomas in two or more members of the same family in the absence of other syndromic clinical features. > AIP appears to act as a tumor suppressor gene (TSG) (3). It is a cytoplasmic protein and a co-chaperone of heat-shock protein 90 (HSP90), and several studies demonstrated the involvement of AIP in various nuclear receptor signaling pathways, such as in estrogen receptor α (ERA) and glucocorticoid receptor (GR) signaling pathways (4,5,6). However, the exact molecular mechanisms by which AIPmut promotes pituitary adenomas are unclear. There is evidence that a failure to inhibit cyclic adenosine monophosphate (cAMP) synthesis underlies the development of pituitary adenomas in AIPmut patients (7). The observation of loss of heterozygosity (LOH) at the chromosome 11q13 in pituitary adenomas containing AIPmut provides another argument for the role of these genetic mutations in pituitary tumorigenesis (3,8). Functional evaluation of AIPmut has shown reduced ability to inhibit cell proliferation and disruption of the protein-protein interaction between AIP and phosphodiesterase-4A5 (PDE4A5) (9).

[2] Landscape of Molecular Events in Pituitary Apoplexy

Authors: Prakamya Gupta, P. Dutta
Year: 2018
Venue: Frontiers in Endocrinology
URL: https://www.semanticscholar.org/paper/55e86f595e73f18ecf8b038db544a8418d4e7264
DOI: 10.3389/fendo.2018.00107
PMID: 29615979
PMCID: 5869273
Citations: 21
Summary: The various proteins/cytokines/growth factors and signaling molecules which are involved in the pathogenesis of pituitary apoplexy and their potential role as biomarkers or as therapeutic targets are discussed.
Evidence snippets:
Snippet 1 (score: 0.577) > Pituitary apoplexy is currently defined as a clinical symptom that can be confirmed radiologically or pathologically. Due to scanty literature in the field, this review proposes the possible underlying pathways responsible for pituitary apoplexy in terms of analyzing a bunch of molecular targets, i.e., VEGF, TNF-α, HIF-1α, MMP-2/9, PTTG, and Ki-67. The analysis of possible constituents of pituitary apoplexy pathways is seemingly relative not encircling the long list of predefined molecules. However, including basic molecular studies of cell damage, namely intrinsic (cellular suicide, e.g., apoptosis) and extrinsic (external threat from surrounding) pathways will help in deciphering the exact mechanism of pituitary apoplexy. Moreover, unknown genes, cytokines, proteins might be involved in two major phenomena such as hemorrhage and infarction by being most effective pathogenetic mechanisms of pituitary apoplexy. > Despite extensive research on pituitary adenoma, there is scanty literature on the etio-pathogenesis of apoplectic pituitary adenoma. Genomics, proteomic, and metabolomics study on large sample sizes are needed to better understand the mechanism and thus may help in the management of patients with pituitary apoplexy.

[3] Novel Insights into Pituitary Tumorigenesis: Genetic and Epigenetic Mechanisms

Authors: Vinaya Srirangam Nadhamuni, M. Korbonits
Year: 2020
Venue: Endocrine Reviews
URL: https://www.semanticscholar.org/paper/73f7cd16dd35ae141782ba38f0bb1d6f046e86cc
DOI: 10.1210/endrev/bnaa006
PMID: 32201880
PMCID: 7441741
Citations: 76
Influential citations: 1
Summary: Insights from the recent developments in the regulation of pituitary tumorigenesis are summarized and best studied in the emerging multiomics studies.
Evidence snippets:
Snippet 1 (score: 0.514) > • An increasing number of genes with germline mutations are known now to be associated with pituitary tumors, some causing syndromic disease while others isolated pituitary adenomas. > • Gain-of-function somatic mutations are common in somatotropinomas in the GNAS gene and in corticotropinomas in USP8. > • Other, less common somatic variants recently identified through next generation sequencing need to be confirmed in independent cohorts and elucidated through functional studies in the future. > • Epigenetic modifications (DNA methylation, histone modification, and noncoding RNAs) can greatly influence tumorigenesis and tumor characteristics such as subtype differentiation and local invasion. > • An integrated multiomics approach to characterize genetic and epigenetic pathways allows better understanding the molecular mechanisms that underlie pituitary tumorigenesis within and across the various subtypes and may lead to the identification of better prognostic factors. > although mostly identified as de novo mutation, has also been described in families (three kindreds described so far in the literature (25)(26)(27)(28)). However, patients with a suggestive family history with no known genetic cause form the majority of patients with FIPA. AIP mutation-positive pituitary tumors. The AIP gene maps to chromosome 11q13. 2 (29)(30)(31). The cAMP/ protein kinase A/phosphodiesterase pathway plays a key role in somatotroph physiology and acromegaly-related genetic syndromes (Fig. 3). Not surprisingly, therefore, a link has been found between this pathway and AIP at several levels: at the inhibitory Gαi-2 protein (32,33), at cAMP (34), at phosphodiesterase 4A (35)(36)(37), at protein kinase A (38,39), downstream of somatostatin receptors, and Zac1 (40,41) levels. AIP has also found interact and inhibit the endoplasmatic reticulum calcium channel ryanodine receptor in C. elegans (31), another pathway closely linked with hormone release, with somatic variants identified in calcium-related pathways in somatotrop

[4] Aggressive prolactinoma in a child related to germline mutation in the ARYL hydrocarbon receptor interacting protein (AIP) gene.

Authors: L. Naves, M. Jaffrain-Rea, S. Vencio, C. Jacomini, L. Casulari et al.
Year: 2010
Venue: Arquivos brasileiros de endocrinologia e metabologia
URL: https://www.semanticscholar.org/paper/cdacdb557de8fdaa8d5577e9fd5d2969047ecc9c
DOI: 10.1590/S0004-27302010000800017
PMID: 21340166
Citations: 19
Summary: Germline mutations in the AIP gene may be involved in the predisposition to pituitary adenoma formation, as cause or co-factor in pathogenesis of aggressive tumors in young patients.
Evidence snippets:
Snippet 1 (score: 0.502) > C linically relevant pituitary adenomas have a preva- lence of 1 case per 1064-1289 of the population and prolactinomas are the most common comprising 57%-66% of the total (1,2). As with all pituitary adenomas, prolactinomas are unfrequent in childhood, only about 3.5%-8.5% of pituitary adenomas are diagnosed before the age of 20 years and an indolent course may mean that tumors occurring in adolescents are not actually diagnosed until early adulthood (3,4). > Clinical presentation in childhood is variable and symptoms related to tumor growth are the most prevalent. In young children, decrease in growth velocity is a rare symptom, what could contribute to subclinical disease evolution and the delay in diagnosis. Impairment of gonadal axis is the most frequent endocrine disorder in late childhood and adolescence, leading to delayed puberty (4-6). > First-line treatment of prolactinomas relies on dopamine agonists, such as, cabergoline, and relative or complete resistance is very uncommon. Clinical factors associated with tumor aggressiveness and resistance to dopamine agonists include young age at onset, male gender, large tumor size or cavernous sinus invasion at diagnosis (7)(8)(9)(10). > Despite many genetic abnormalities being described, the molecular pathophysiology of prolactinomas, particularly those with an aggressive clinical course, remains largely obscure. Recently, germline mutations in the aryl hydrocarbon receptor interacting protein (AIP) gene, were reported to be involved in the predisposition to pituitary adenoma formation (11,12). > Patients with AIP mutations have pituitary adenomas at a younger age, which are often large at diagnosis, suggesting an aggressive phenotype. These tumors usually occur in the familial isolated pituitary adenomas (FIPA) setting (13,14) and sporadic pituitary tumors firstly appeared to be very rare (15)(16). Recently, AIP mutations related to sporadic tumors have been increasingly reported in young patients (17,18).

[5] Childhood Multiple Endocrine Neoplasia (MEN) Syndromes: Genetics, Clinical Heterogeneity and Modifying Genes

Authors: F. Lanzaro, Delia De Biasio, Francesco Giustino Cesaro, E. Stampone, I. Tartaglione et al.
Year: 2024
Venue: Journal of Clinical Medicine
URL: https://www.semanticscholar.org/paper/bfd33b0ef807e95dcdeccab919ca54b88638745d
DOI: 10.3390/jcm13185510
PMID: 39336996
PMCID: 11432259
Citations: 3
Summary: Understanding factors and genetic variants that control cellular functions and the expression of disease genes should provide insights into fundamental disease processes, providing implications for counseling and therapeutic and prophylactic possibilities.
Evidence snippets:
Snippet 1 (score: 0.494) > As described before, the MEN1 phenotype varies between patients in terms of tumor localization, age of onset, and clinical aggressiveness, even between affected members within the same family. Additional co-segregating modifying factors, such as germline mutations in other genes, or epigenetic changes or post-translational protein modifications, likely contribute to the interfamilial variability of MEN 1 [18]. > For example, the gene encoding for the aryl hydrocarbon receptor interacting protein (AIP) is located on 11q13, near the MEN1 gene but approximately 3 mb away. Inactivating mutations and deletions in the AIP gene predispose individuals to low-penetrance pituitary adenomas. Concurrent deletions involving these genes may contribute to predisposition to MEN1 and pituitary adenoma [71], as has been already postulated for the pathogenesis of the brown fat tumor hibernoma [72]. Although no preclinical models or clinical direct evidence have been produced in the MEN1 setting, patients with particularly aggressive pituitary adenomas associated with MEN1 syndrome might be considered for either AIP gene analysis or expression and functional protein assessments, which could help explain the aggressive phenotype. > The aryl hydrocarbon receptor-interacting protein (AIP) is a relatively understudied HSP90 and HSC70 co-chaperone, consisting of 330 amino acids, with a potential role as both a tumor suppressor and an oncogene involved in the cAMP-phosphodiesterase pathway. Common AIP variants (AIPvar) include nonsense and missense mutations, deletions, insertions, splice-site and promoter mutations, and large deletions, most of which lead to a truncated protein or, less commonly, affect the tetratricopeptide repeat (TPR) domains or the C-terminal α-helix.

[6] Expression and Clinical Significance of miR-26a and Pleomorphic Adenoma Gene 1 (PLAG1) in Invasive Pituitary Adenoma

Authors: Chuan-ting Yu, Jixia Li, Fengnan Sun, Jinpeng Cui, Huali Fang et al.
Year: 2016
Venue: Medical Science Monitor : International Medical Journal of Experimental and Clinical Research
URL: https://www.semanticscholar.org/paper/4615a7684601a27e4dac6bda9456ff79de0942bc
DOI: 10.12659/MSM.898908
PMID: 28012286
PMCID: 5207015
Citations: 28
Summary: MiR-26a can facilitate occurrence of pituitary tumor and invasiveness, probably via inhibiting PLAG1 expression.
Evidence snippets:
Snippet 1 (score: 0.474) > Pituitary tumors are monoclonal tumors originating from residual epithelial cells of anterior/posterior pituitary and cranial-pharyngeal tissues, and account for about 10~15% of all intracranial tumors. A previous study has confirmed the benign nature of most pituitary tumors. Clinically, however, about onethird of all pituitary tumors showed invasive growth, which is a biological behavioral of malignant tumors. Such pituitary adenomas often show aggressive growth toward peripheral tissues/nerves, and thus are termed invasive pituitary tumors. Invasive pituitary tumors have rapid progression, are difficult to completely removal during surgery, and have higher shortterm recurrence rate after surgery, making clinical treatment a major challenge. The invasive growth of pituitary tumor is one important factor causing the recurrence of disease, further affecting clinical treatment efficacy and prognosis. Recent studies have focused on the mechanism directing pituitary tumor proliferation, activation of oncogenes, and inactivation of tumor suppression genes, but the biological mechanism affecting tumor invasion/migration is still not fully understood. For instance, CCND1 gene, a proto-oncogene, plays a role in pituitary tumorigenesis and invasiveness and its polymorphism in patients with different types of sporadic pituitary adenomas were determined [21]. Hypoxia can increase the expression of DDR1, a newly discovered kind of tyrosine kinase receptor on the cell surface, which in turn promotes pituitary adenoma cell proliferation and invasion [22]. In particular, a recent finding showed that the expression of Cold-Inducible RNA-Binding Protein (CIRP) in pituitary adenomas is closely related with tumor proliferation and invasion, and its significantly elevated expression level indicates post-operative recurrence [23]. Therefore, understanding the invasion/migration mechanism and identifying the specific molecular marker for acquiring invasion/migration property are of critical importance for early diagnosis of pituitary tumors, broadening clinical treatment strategy, improving treatment efficacy, and guiding individualized treatment. With the advancement of molecular biology, the pathogenesis mechanism of IPA has been illustrated from the molecular level by some scholars.

[7] Isolated familial somatotropinoma: 11q13-loh and gene/protein expression analysis suggests a possible involvement of aip also in non-pituitary tumorigenesis

Authors: R. Toledo, B. Mendonca, M. Fragoso, I. Soares, M. Almeida et al.
Year: 2010
Venue: Clinics
URL: https://www.semanticscholar.org/paper/7baae2cb07fdafba37f12c628dd34c158b8096be
DOI: 10.1590/S1807-59322010000400010
PMID: 20454499
PMCID: 2862671
Citations: 35
Summary: The finding of AIP inactivation in the adrenocortical tumor suggests that further investigation of the potential role of this recently identified tumor suppressor gene in non-pituitary tumors, mainly in those tumors in which the cAMP and the 11q13 locus are implicated, is likely to be worthwhile.
Evidence snippets:
Snippet 1 (score: 0.472) > Acromegaly/gigantism is characterized by excess of growth hormone (GH) largely due to GH-secreting pituitary adenomas. 1 Although most cases are sporadic, familial forms may occur in association with inherited syndromes such as Multiple Endocrine Neoplasia type 1 (MEN1), Carney complex (CNC), pituitary adenoma predisposition (PAP) and familial isolated pituitary adenoma (FIPA), which includes isolated familial somatotropinoma (IFS). [2][3][4] Germline mutations and somatic inactivation of the aryl hydrocarbon receptor-interacting protein (AIP) gene have been recently identified in patients with PAP. 2 The role of AIP in FIPA patients has been confirmed, and more than thirty different AIP inactivating mutations have been identified throughout the gene. 5 GH-, GH/PRL-and PRLsecreting pituitary adenomas are the most common clinical features of AIP mutation carriers, although ACTH-secreting and non-functioning pituitary adenomas have also been reported. 5,6 AIP mutations account for approximately 15% of families with FIPA and 50% of IFS families. 3,5 While AIP mutations appear to be very rare in cases with sporadic pituitary disease, 7,8,9 they are more frequently found in children and adolescents with GH-secreting tumors, even in the absence of family history. 10 Although no systematic clinical surveys of non-pituitary neoplasia have been reported, concomitant non-pituitary tumors, including thyroid, adrenal and MEN1-related tumors were reported in a subset of AIP mutation-positive PAP and FIPA families 10,11 and Prof. Albert Beckers, FIPA Meeting, Liège 2009 (unpublished data). The fact that AIP interacts with phosphodiesterases type 4A (PDE4A) and type 2A (PDE2A) implicates this gene in the cyclic AMP (cAMP) signaling cascade, 12,13 a cellular pathway known to be disrupted in pituitary, but also in thyroid and ad

[8] Macroprolactinoma in a Patient With Schizophrenia: A Therapeutic Challenge

Authors: E. Voelz, L. Matias, M. Student, M. Medeiros, Murilo D Pimentel
Year: 2021
Venue: Journal of the Endocrine Society
URL: https://www.semanticscholar.org/paper/696f918472b1dded0b3170d8b7f6ddd4f0946979
DOI: 10.1210/jendso/bvab048.1206
PMCID: 8090302
Citations: 1
Summary: It is necessary to analyze prolactin levels, imaging tests and the prescription of antipsychotic medications for correct analysis and evaluation of prolact inomas in schizophrenic patients.
Evidence snippets:
Snippet 1 (score: 0.469) > Background: Germline mutations in the Aryl hydrocarbon receptor-Interacting Protein (AIP) gene are associated with pituitary adenomas in young patients usually in the setting of Familial Isolated Pituitary Adenomas (FIPA). The majority of these adenomas are somatotropinomas followed by prolactinomas, and rarely non-secreting adenomas. AIP-mutation-related prolactinomas predominantly affect men, as opposed to sporadic prolactinomas, that typically affect women. Clinical Case: We previously described an AIP gene mutation in two patients affected by prolactinomas. During the past years, we continued our study and have identified two more male patients with macroprolactinomas originally from the same small village and harboring the same AIP gene mutation. These male patients aged 19 to 44 years at the time of diagnosis. Two of them had neurological manifestations as the first clinical manifestation of the disease, one was studied because of hypogonadism and two patients had visual field defects. All of them had prolactin levels above 1000 ng/dl (mean 2946.5±948.7 ng/dl, reference range 10-21). In the imaging exams (CT/MRI) they presented pituitary adenomas larger than 20 mm (macroprolactinomas) and in two of the cases, the adenomas were even larger than 40 mm (giant prolactinomas). In order to exclude mutations most often associated with prolactinomas, DNA samples were obtained and analyzed by Next Generation Sequencing (NGS) using TruSightCancer Gene Set (Illumina) methodology. Investigation of significant deletions and/or duplications was performed using the MLPA (Multiplex ligation-dependent probe amplification) technique. None of the patients were positive for mutations of Multiple Endocrine Neoplasia type 1 (MEN1) gene. A variant of the AIP gene c.47G>A, expecting to lead to a substitution of arginine by histidine at position 16 (p.Arg16His) of the AIP was found in these four patients, including a father and his son.

[9] Aryl hydrocarbon receptor (AHR) is a potential tumour suppressor in pituitary adenomas

Authors: Robert Formosa, J. Borg, J. Vassallo, J. Vassallo
Year: 2017
Venue: Endocrine-Related Cancer
URL: https://www.semanticscholar.org/paper/d93ab1b8deb2488ce89e9c686679c1c6ecf1118b
DOI: 10.1530/ERC-17-0112
PMID: 28649092
PMCID: 5541251
Citations: 28
Influential citations: 1
Summary: Functional studies support a mechanistic pathway for the putative tumour suppressive role of AHR specifically in PA, possibly through its role as a cell cycle co-regulator, even in the absence of exogenous ligands.
Evidence snippets:
Snippet 1 (score: 0.464) > Pituitary adenomas (PA) represent the commonest cranial neoplasms and vary in size, type and aggressiveness.Clinically relevant PAs result in symptoms due to hormonal hypersecretion, intracranial mass effects or secondary hypopituitarism and locally occur with an average prevalence of approximately 76/100,000 (Gruppetta et al. 2013).The vast majority of PAs are sporadic in origin with only a small number of significant genetic mutations identified in relatively rare familial cases and endocrine syndromes.The heterogenous nature of PAs poses challenges in the elucidation of the molecular mechanisms driving their formation and progression 24:8 (Asa et al. 2017).This contrasts significantly with current knowledge in relation to malignant tumours. > Certain key pathways have already garnered a great deal of attention, including the cAMP secondary messenger signalling pathway, the Wnt signalling pathway and the pI3K/Akt signalling pathways (Chambers et al. 2013, Formosa & Vassallo 2014, Monsalves et al. 2014, Peverelli et al. 2014).However, even collectively, these molecular pathways do not cater for the entirety of the mechanisms that are responsible for the development and/or progression of PAs, making our understanding of the disease as yet limited.Several studies using highthroughput techniques including microarray studies and large-scale sequencing have identified a number of interesting pathways (Moreno et al. 2005, Morris et al. 2005, Evans et al. 2008, Jiang et al. 2010, Newey et al. 2013, Valimaki et al. 2015).In an attempt to uncover more molecular mechanisms driving Pas, we screened RNA profiles expressions of local tumours to uncover common altered pathways among a heterogeneous set of PAs.A consistently altered pathway observed implicated xenobiotic signalling. > The AHR is a ligand-activated transcription factor containing the basic helix-loop-helix (bHLH)/PAS domain mediating the response to a variety of environmental toxins (Burbach et al. 1992).

[10] The Mechanism and Pathways of Dopamine and Dopamine Agonists in Prolactinomas

Authors: Xiaoshuang Liu, Chao Tang, Guodao Wen, C. Zhong, Jin Yang et al.
Year: 2019
Venue: Frontiers in Endocrinology
URL: https://www.semanticscholar.org/paper/cb3b81abdb92e83c8be21aa966cb4926c31e4cd2
DOI: 10.3389/fendo.2018.00768
PMID: 30740089
PMCID: 6357924
Citations: 49
Influential citations: 2
Summary: The main aim of this paper is to review the different pathways of dopamine and its agonists in prolactinomas to help to gain a better understanding of their functions and drug resistance mechanisms.
Evidence snippets:
Snippet 1 (score: 0.461) > Pituitary adenomas (PAs) are common intracranial neoplasms. Typically, PAs are classified as either clinically non-functioning PAs or functioning PAs with characteristic clinical and endocrine symptoms, such as acromegaly and hyperprolactinemia or Cushing disease (1,2). > Prolactinomas are the most common type of functioning PAs, which can cause headache, visual dysfunction, hypopituitarism, and hyperprolactinemia (3). The clinical features of hyperprolactinemia include impotence in males and oligo/amenorrhea in females (4,5). The normalization of serum prolactin (PRL) levels and shrinkage of tumors are among the major goals of treatment in patients with prolactinomas (6). Dopamine agonists (DAs), such as bromocriptine (BRC) and cabergoline (CAB) are the first-line drugs for the treatment of patients with idiopathic hyperprolactinemia and prolactinomas (3,7). The lactotroph adenoma cells express dopamine receptors, and DAs effectively suppress prolactin secretion and shrink the tumor by binding the cell-surface dopamine receptors in most patients (7,8). This suggests that a "gene-network" may exist to regulate the activation of dopamine receptors, and may be involved in the mechanism of action of DAs for the treatment prolactinomas. > Although, two main DAs, namely BRC and CAB, have been approved as first-line drugs for the treatment of patients with hyperprolactinemia, a minority of patients with prolactinoma were resistant or intolerant to BRC, but responded adequately to CAB (9,10). Currently, a better understanding of the pathophysiology of prolactinomas and the precise mechanisms of action of DAs in prolactinomas is greatly needed, especially considering that different pharmacological compounds act on lactotroph cells through different intracellular molecular pathways.

[11] Dopamine and Somatostatin Analogues Resistance of Pituitary Tumors: Focus on Cytoskeleton Involvement

Authors: E. Peverelli, D. Treppiedi, E. Giardino, E. Vitali, A. Lania et al.
Year: 2015
Venue: Frontiers in Endocrinology
URL: https://www.semanticscholar.org/paper/2151b0fde86089f4889837a105353c2a28daa73e
DOI: 10.3389/fendo.2015.00187
PMID: 26733942
PMCID: 4686608
Citations: 36
Influential citations: 2
Summary: An overview of the known molecular events involved in SS and DA resistance is provided, focusing on the role played by FLNA in DRD2 and SSTRs receptors expression and signaling in PRL- and GH-secreting tumors.
Evidence snippets:
Snippet 1 (score: 0.460) > FiGURe 1 | Schematic representation of the possible molecular mechanisms involved in drug resistance of pituitary tumors. DA-resistance in PRL-secreting tumors might be related to a defective expression of DRD2 or to an altered expression of specific splice variants. Genetic alterations of DRD2 or possible alterations in the molecules involved in receptor internalization or signal transduction culminating in the inhibitory action on PRL secretion and cell proliferation might also be involved. SS-resistance of GH-secreting tumors, besides to reduced SSTR2 and/or SSTR5 expression, rarely associated with mutations of SSTR2 and SSTR5 genes, but it has been correlated with the expression of truncated variatns of SSTR5 (SST5TMD4). Asterisk indicates the only mutational change found in the SSTR5 gene (R240W, in the third intracellular loop). Alterations in signal transduction may include G proteins, AIP, or arrestins. tumorigenic somatotroph cells is the cause of gigantism during childhood and acromegaly in adults, with significant morbidity due to clinical complications involving cardiovascular, respiratory, and metabolic systems. Adenocorticotroph hormone (ACTH)secreting tumors cause Cushing's disease (hypercortisolism), and TSH-secreting tumors present with signs and symptoms of hyperthyroidism. Non-functioning pituitary tumors (NFPAs) are hormonally inactive, and patients with this tumor type often present with neurological symptoms due to the mass effect. > Pituitary tumors frequently preserve responsiveness to hypophysiotropic factors, including dopamine (DA) and somatostatin (SS), ubiquitous peptides that physiologically inhibit hormone secretion and cell proliferation at both the pituitary and the periphery levels, and thus are considered as molecules with therapeutical potential (1).

[12] Molecular subtypes of adamantinomatous craniopharyngiomas

Authors: Wenhao An, Shouwei Li, Yihua An, Zhixiong Lin
Year: 2025
Venue: Neuro-Oncology
URL: https://www.semanticscholar.org/paper/143003e08778ae31fc11732445c3ba4c90c178de
DOI: 10.1093/neuonc/noaf030
PMID: 39898434
PMCID: 12187517
Citations: 9
Influential citations: 1
Summary: This review focuses on summarizing and synthesizing the molecular mechanisms and potential subtypes of ACP, aiming to provide theoretical support for future research on the molecular subtyping of ACP.
Evidence snippets:
Snippet 1 (score: 0.456) > Growth pattern of the tumor around the arachnoid sleeve near the pituitary stalk -Q type: tumor originating from the area below the sellar diaphragm -S type: tumor originating from the suprasellar pituitary stalk area -T type: tumor originating from the infundibular tubercle region of multiple signaling pathways and molecular mechanisms, including Wnt/β-catenin, MAPK, SHH, and others, which play significant roles in the formation and progression of ACPs. In recent years, with the application of high-resolution technologies such as single-cell RNA sequencing, researchers have gradually revealed significant heterogeneity within ACP tumors. 101 This internal heterogeneity also leads to considerable differences in the clinical presentations of patients with ACP. 102 For example, the age of onset varies widely, affecting both children and adults; radiologically, ACP can present in various forms, including cystic, solid, or a combination of cystic and solid components. 103 These diverse presentations contrast sharply with the traditional view of ACP as a tumor driven solely by single-gene mutations. More notably, different patients also exhibit significant variability in their responses to drug treatments. 104 For example, some patients respond well to anti-inflammatory therapy and achieve disease control, whereas others may show no significant response to the same treatment. 15 These findings further suggest that ACP might exist in different molecular subtypes, each with distinct mechanisms of onset, progression, and treatment response. Tumor classification has gradually shifted from histological to molecular subtyping, and new molecular subtyping is not only the basis for precision therapy but also crucial for elucidating tumor mechanisms, identifying prognostic factors, and developing personalized treatment strategies. 105,106 esearch on the molecular subtyping of ACP has evolved from the discovery of single-gene mutations to comprehensive multiomics analyses. 8][109] Subsequently, specific epigenetic markers, such as DNA methylation and histone modifications, were identified, revealing different patterns among numerous ACP patients. 110

[13] Benzene and 2-ethyl-phthalate induce proliferation in normal rat pituitary cells

Authors: Laura Tapella, A. Sesta, M. Cassarino, V. Zunino, M. Catalano et al.
Year: 2016
Venue: Pituitary
URL: https://www.semanticscholar.org/paper/26fa892152dc373704774d4f86a3d83030c7433b
DOI: 10.1007/s11102-016-0777-3
PMID: 27853917
PMCID: 5427103
Citations: 19
Influential citations: 1
Summary: These findings indicate that benzene and 2-ethyl-phthalate activate AhR/AIP expression and stimulate proliferation in normal rat pituitary cells, the first demonstration that pollutants can induce normal pituitsary cells to proliferate.
Evidence snippets:
Snippet 1 (score: 0.453) > AhR is a cytosolic transcription factor first identified through its dioxin-binding capacity and, indeed, mediates a variety of responses to toxic halogenated aromatic hydrocarbons [22]. AIP acts as chaperone to AhR and facilitates activation of AhR; in turn, activated AhR translocates into the nucleus, heterodimerizes with AhRnuclear translocator (ARNT) and acts upon target genes [46]. The role of this pathway in carcinogenesis is the focus of increasing interest [23] and, indeed, a link to pituitary tumorigenesis was recently detected as germline mutations in AIP were shown to predispose to development of pituitary adenomas [21]. Several studies followed upon this first report in an attempt to clarify the pathogenesis of AIPmutated pituitary tumors but the exact mechanism remains elusive [47,48]. In fact, expression and cellular localization of AIP, AhR and ARNT appear variable with some tumors presenting low AIP, absent nuclear AhR staining and loss of ARNT expression, others increased AIP expression or nuclear AhR staining [49][50][51]. A most recent study in fibroblasts from patients with four different AIP mutations showed that AhR expression was unaffected but that AhR target genes, i.e. CYP1B1, AhR repressor (AHRR), were either reduced or increased depending on the AIP variant [52]. From a clinical viewpoint, patients carrying AIP mutations are more often young, male and with large GH-or mixed GH-and prolactin-secreting tumors [48,53,54]. Interestingly, the AhR gene itself appears to contribute to severity of acromegaly as polymorphisms and variants in AhR have been associated with more aggressive disease [55,56]. > Altogether, it is clear that the AhR-AIP pathway is involved in pituitary tumorigenesis and our findings shed further light into this concept.

[14] Deciphering USP8’s pivotal role in cancer: mechanisms, clinical insights and contrasts with its function in pituitary adenomas

Authors: Li-ping Song, Dexu Kong, Lina Yang
Year: 2025
Venue: Journal of Translational Medicine
URL: https://www.semanticscholar.org/paper/a17537fe741b548059ecdbc5aaae7b918a826eb0
DOI: 10.1186/s12967-025-07530-y
PMID: 41331709
PMCID: 12777360
Summary: This review systematically summarizes USP8’s context-dependent roles in cancer biology, dissects the mechanistic basis for its divergent effects in cancers and pituitary adenoma, and highlights its clinical value as a differential biomarker and unifying therapeutic target across tumor types.
Evidence snippets:
Snippet 1 (score: 0.444) > As a core member of the ubiquitin-specific protease (USP) family, USP8 functions as a pivotal deubiquitinating enzyme that orchestrates fundamental biological processes. Its dysregulation has been firmly established as a key driver in the initiation and progression of cancers, while its activating mutations also play a determinant role in the pathogenesis of Cushing's disease-associated pituitary adenomas-specifically promoting adenoma growth and excessive ACTH secretion. This review systematically synthesizes three interconnected dimensions of USP8 research to construct a comprehensive understanding of its role in tumor biology and related disorders. First, it dissects the context-dependent molecular mechanisms through which USP8 exerts divergent biological effects across tumor types, with a focus on how its modulation of substrate proteins such as EGFR shapes distinct pathogenic cascades. Second, it delineates the clinical utility of USP8 as a diagnostic and prognostic biomarker, highlighting its potential to guide treatment decision-making. Third, it evaluates the translational potential of USP8 as a therapeutic target, underscoring its relevance for developing targeted interventions across disease entities. > A central innovative insight of this review lies in its identification of a cross-disease functional linkage for USP8. Through integrated analysis of existing evidence, we demonstrate that USP8 activates distinct molecular pathways via its shared substrate EGFR, ultimately driving disparate biological outcomes in cancers and benign pituitary adenomas. This finding not only provides a novel mechanistic framework for unifying research on cancers and pituitary adenoma but also expands the therapeutic landscape by positioning USP8 as a common target with relevance across diverse pathological contexts. Such a cross-disease perspective addresses a long-standing gap in the field, where cancer and benign pituitary adenoma research involving USP8 has largely proceeded in isolation. > Beyond bridging the divide between cancer and benign pituitary adenoma biology, USP8 serves as a central regulatory node that coordinates multiple cancer-related biological processes, modulates key tumor-associated molecular mechanisms, and offers actionable insights for translational medicine and clinical practice.

[15] Somatic Deletion in Exon 10 of Aryl Hydrocarbon Receptor Gene in Human GH-Secreting Pituitary Tumors

Authors: A. Re, F. Ferraù, C. Cafiero, F. Spagnolo, V. Barresi et al.
Year: 2020
Venue: Frontiers in Endocrinology
URL: https://www.semanticscholar.org/paper/f9be55a775b0bff5854394553f4bc757f74a73b0
DOI: 10.3389/fendo.2020.591039
PMID: 33281746
PMCID: 7689685
Citations: 7
Summary: This is the first demonstration of a recurrent somatic deletion in the exon 10 of the AHR gene in somatotropinomas, and the functional impact of this genetic finding needs to be clarified.
Evidence snippets:
Snippet 1 (score: 0.442) > AHR is a ligand-activated transcription factor that can bind over 400 different endogenous and exogenous compounds, including several endocrine disrupting chemicals and environmental contaminants (17)(18)(19). AHR activation leads to the transactivation of genes encoding phase I and II xenobiotics metabolizing enzymes, thus representing a key factor of the intracellular detoxification systems (20). The AHR has been therefore studied mainly in the context of environmental pollutants processing as transcriptional regulator of genes involved in the metabolism and/or excretion of toxins such as dioxin TCDD (21). Moreover, AHR is directly or indirectly involved in many other biologically relevant processesvia the so-called non-canonical pathwayssuch as cell cycle regulation and cell contact inhibition, potentially contributing to tumorigenesis (22)(23)(24). A limited number of studies has focused on the impact of AHR signaling in PA. Jaffrain-Rea in 2009 reported that the AHR and its partner AIP were downregulated in aggressive somatotropinomas as compared to non-invasive adenomas suggesting their involvement in the acquisition of an aggressive phenotype (25). Subsequently, several groups focused their attention on the uncovered link between AHR and/or AIP expression and the molecular mechanisms underlying pituitary adenoma pathogenesis. AIP, a co-chaperone protein that acts as a tumor suppressor in pituitary cells (26), is critical for AHR stabilization and function. AIP gene germline mutations have been found in young patients with familial or apparently sporadic aggressive pituitary adenomas, mostly secreting GH and/or PRL, and less responsive to conventional medical treatments (27). Moreover, although it is still a matter of debate, AIP mutations also affect the AHR signaling, since they can alter the AHR and phosphodiesterase (PDE)4A5 interaction and consequently the cAMP pathway, affecting pituitary function and tumorigenesis (22,28).

[16] Phenotype-Genotype Association Analysis of ACTH-Secreting Pituitary Adenoma and Its Molecular Link to Patient Osteoporosis

Authors: Renzhi Wang, Yakun Yang, Miaomiao Sheng, Dechao Bu, Fengming Huang et al.
Year: 2016
Venue: International Journal of Molecular Sciences
URL: https://www.semanticscholar.org/paper/5b1f65eaaabf469aee5b143df5e58601a2eecc95
DOI: 10.3390/IJMS17101654
PMID: 27690016
PMCID: 5085687
Citations: 7
Summary: A novel analysis linking disease clinical characteristics and whole transcriptomic changes, using Pearson Correlation Coefficient to discover a molecular network mechanism for osteoporosis in CD patients is developed and it is reported that osteoporeosis is distinguished from the phenotype and genotype analysis.
Evidence snippets:
Snippet 1 (score: 0.442) > Adrenocorticotrophin (ACTH)-secreting pituitary adenoma, also known as Cushing disease (CD), is rare and causes metabolic syndrome, cardiovascular disease and osteoporosis due to hypercortisolism. However, the molecular pathogenesis of CD is still unclear because of a lack of human cell lines and animal models. Here, we study 106 clinical characteristics and gene expression changes from 118 patients, the largest cohort of CD in a single-center. RNA deep sequencing is used to examine genotypic changes in nine paired female ACTH-secreting pituitary adenomas and adjacent nontumorous pituitary tissues (ANPT). We develop a novel analysis linking disease clinical characteristics and whole transcriptomic changes, using Pearson Correlation Coefficient to discover a molecular network mechanism. We report that osteoporosis is distinguished from the phenotype and genotype analysis. A cluster of genes involved in osteoporosis is identified using Pearson correlation coefficient analysis. Most of the genes are reported in the bone related literature, confirming the feasibility of phenotype-genotype association analysis, which could be used in the analysis of almost all diseases. Secreted phosphoprotein 1 (SPP1), collagen type I α 1 chain (COL1A1), 5′-nucleotidase ecto (NT5E), HtrA serine peptidase 1 (HTRA1) and angiopoietin 1 (ANGPT1) and their signalling pathways are shown to be involved in osteoporosis in CD patients. Our discoveries provide a molecular link for osteoporosis in CD patients, and may open new potential avenues for osteoporosis intervention and treatment.

[17] CCNB1 affects cavernous sinus invasion in pituitary adenomas through the epithelial–mesenchymal transition

Authors: Bin Li, Jianhua Cheng, Hongyun Wang, Sida Zhao, Haibo Zhu et al.
Year: 2019
Venue: Journal of Translational Medicine
URL: https://www.semanticscholar.org/paper/ce00533d98ea744f75ca3e7bec07198a28fabd0f
DOI: 10.1186/s12967-019-2088-8
PMID: 31585531
PMCID: 6778375
Citations: 22
Summary: High CCNB1 expression in pituitary adenoma affects cavernous sinus invasion through EMT, and downregulation ofCCNB1 led to reduced cell invasion and migration in Transwell experiments.
Evidence snippets:
Snippet 1 (score: 0.439) > Pituitary adenoma is one of the most common nervous system tumours, accounting for approximately 10-15% of intracranial tumours. The incidence of pituitary adenomas has increased in recent years [1,2]. Some pituitary adenomas are invasive, leading to the enclosure and compression of important adjacent structures, including the cavernous sinus, making surgery and treatment difficult. Pituitary adenomas that invade the cavernous sinus area account for 6-10% of all pituitary adenomas [3]. These refractory pituitary adenomas adversely affect patient survival and quality of life [4,5]. The clinical diagnosis and treatment of pituitary adenomas that invade the cavernous sinus are fraught with difficulties and challenges, such as difficulties in preoperative classification, inaccurate predictions of prognosis, incomplete tumour resections, postoperative recurrences and drug resistance. Therefore, exploring the biological characteristics of pituitary adenomas that invade the cavernous sinus and studying the molecular biological mechanism involved in their occurrence and development will help to resolve the abovementioned difficulties in clinical diagnosis and treatment, thus improving the pituitary adenoma cure rate, reducing the recurrence of pituitary adenoma, and improving the prognosis of patients. Cyclin B1, which is encoded by the CCNB1 gene, belongs to the cyclin family of cell cycle proteins. Previous studies have demonstrated that the CCNB1 gene is highly expressed in pituitary adenomas and is associated with invasiveness, suggesting that the CCNB1 gene plays an important role in the genesis and development of pituitary adenomas [6]. Similarly, CCNB1 was shown to be closely involved in the pathogenesis of pituitary adenomas in Zhang's research [7]. > Our subsequent research found that suppressing the CCNB1 gene can regulate the proliferation and apoptosis of pituitary tumour cells and activate the epithelialmesenchymal transition (EMT) process. These findings may provide important knowledge for understanding the biological mechanisms of CCNB1 in the development and progression of pituitary adenoma.

[18] Endocrine disrupting chemicals: effects on pituitary, thyroid and adrenal glands

Authors: Filippo Egalini, L. Marinelli, Mattia Rossi, G. Motta, N. Prencipe et al.
Year: 2022
Venue: Endocrine
URL: https://www.semanticscholar.org/paper/4a981ef0d60e8b2a306c63b75946f54e7d0c1d5b
DOI: 10.1007/s12020-022-03076-x
PMID: 35604630
PMCID: 9637063
Citations: 47
Influential citations: 1
Summary: Current evidence regarding the detrimental effects of EDCs on pivotal endocrine glands like pituitary, thyroid and adrenal ones are summarized and the known and the hypothesized mechanisms of endocrine dysfunction brought by EDCs are directed at.
Evidence snippets:
Snippet 1 (score: 0.436) > The pituitary gland is a potential target of EDCs, which can result in an alteration of the pituitary hormonereleasing patterns. The hypophysis seems to be vulnerable through direct and hypothalamic-mediated processes exerted by these compounds [1,17]. However, EDCs mechanisms of action are still not fully figured out: over the entire lifespan of the individual, they could interfere with endogenous hormonal function, affecting the homeostatic system, or alter the genomic expression, e.g., through DNA methylation [1,12]. > A growing body of evidence is suggesting that EDCs can have an influence on tumorigenesis. Researchers described a link between EDCs and cancer burden, particularly with testicular, breast and prostate cancer [1]. Pituitary gland seems to be a potential target of these compounds, too. First epidemiological studies reported a higher incidence of pituitary adenomas due to previous exposure to dioxin [18] and a higher incidence of growth hormone-(GH-)secreting adenomas in a highly industrialized area nearby Messina, Italy [19]. Moreover, in vitro studies succeeded in demonstrating correlations between pollutants and stimulation of pituitary cells: benzene and phthalates increased cell proliferation via a deregulation of aryl hydrocarbon receptor (AHR) and AHR-interacting protein (AIP) [20], a tumor suppressor pathway that seems to be involved with other xenobiotics, such as polycyclic aromatic hydrocarbons and PCBs [21]. The involvement of AIP seems to play a key role: in fact, previous studies had already linked AIP gene mutations with familial isolated pituitary adenoma syndrome, familial somatotropinomas, and with apparently sporadic acromegaly [22,23]. Moreover, in clinical practice AIP gene mutations are associated with an aggressive disease phenotype, which is less responsive to conventional medical treatment, as somatostatin analogues [19].

[19] Special issue on molecular genetics in endocrinology.

Authors: M. Azevedo, Regina S. Moisés, S. Antonini
Year: 2012
Venue: Arquivos brasileiros de endocrinologia e metabologia
URL: https://www.semanticscholar.org/paper/2b94ca494ba86e4ddc902f5bd7c5686098e2ac8f
DOI: 10.1590/S0004-27302012000800001
PMID: 23295283
Summary: This special issue aims at describing clinical cases in which molecular research was performed, thus opening opportunities for the publication of novel mutations, and for the presentation of clinical particularities in patients with mutations that have already been described.
Evidence snippets:
Snippet 1 (score: 0.428) > (6). > A number of genetic alterations have been correlated with disorders in growth and sexual development, and in some cases, the genetic profile may predict the phenotype and clinical outcome. From chromosome anomalies to point mutations, studies by Maciel-Guerra and cols. ( 7 16) illustrates the contribution of microRNA detection strategies in the prediction of outcomes, by describing a patient with an aggressive papillary thyroid carcinoma. > In pituitary diseases, better knowledge of the mechanisms involved in tumorigenesis may provide more effective medical therapy. The association of mutations in the AIP gene in patients with familial pituitary adenomas has pointed out a possible role of AIP protein alterations in the development of sporadic pituitary tumors. In this issue, Kasuki and cols. ( 17) investigated the AIP expression in GH-secreting tumors in correlation with response to medical treatment. Boguszewski and cols. ( 18) describe an interesting case in which the two types of multiple endocrine neoplasm coexist, and discuss the genetic findings associated with this condition, whereas multiple endocrine neoplasia type 2 is revisited by Blom and cols. (19) in a description of the rare S891A RET mutation in a patient with medullary thyroid carcinoma. In addition, genetic studies in oncogenic osteomalacia by Chang and cols. (20), and in Frasier (Guaragna and cols. [21]), Cowden's (Lima and cols. [22]) and hyperinsulinism/hyperammonemia (Corrêa-Giannella and cols. [23]) syndromes are presented in this issue. > In the past, knowledge about molecular genetics was important in the management of only a restricted group of patients. Currently, this strategy has become critical for proper monitoring of a large number of patients in different settings (24). Accordingly, the practitioner should be familiar with the indications and potential limitations of genetic testing. > We are honored to participate as invited editors in this Special Edition of ABEM, having the opportunity of getting in contact with high-quality articles.

[20] Cushing’s disease

Authors: F. Castinetti, I. Morange, B. Conte‐Devolx, T. Brue
Year: 2012
Venue: Orphanet Journal of Rare Diseases
URL: https://www.semanticscholar.org/paper/db0a10b862c990be7a0af1fc851042e1c8faad85
DOI: 10.1186/1750-1172-7-41
PMID: 22710101
PMCID: 3458990
Citations: 47
Influential citations: 1
Summary: A review summarizes potential pathophysiological mechanisms, diagnostic approaches, and therapies for Cushing’s disease, which is a rare disease responsible for increased morbidity and mortality.
Evidence snippets:
Snippet 1 (score: 0.428) > Most of these are somatotroph or lactotroph, but corticotroph adenomas have been described in 5-10% of cases. AIP (Aryl hydrocarbon receptor Interacting Protein) mutations have been reported in familial pituitary adenomas: secretion profile is usually somatotroph or lactotroph, whereas very rare cases of CD have also been reported [15]. > Potentially involved molecular mechanisms Triggering signals leading to Cushing's disease remain unclear. Oncogenes do not appear to be involved, as somatic mutations are usually not present in corticotroph adenomas cells. Recent studies in mice identified a potential role of loss of function of Brg1 (brahma-related gene 1) and HDAC2 (Histone Deacetylase 2) in the pathogenesis of Cushing's disease. Both proteins form a complex with the glucocorticoid receptor and the orphan nuclear receptor nuclear growth factor IB (NGFI-B) to repress POMC secretion. Interestingly, about 50% of corticotroph adenomas do not express these proteins anymore. The loss of Brg1 could lead to overexpression of cyclin E, leading to increased cell proliferation and sporadic hyperplasia or tumors. Interestingly, tumors with a loss of nuclear localization of Brg1 seem to be more responsive to anticortisolic drugs in vitro compared to the ones with a complete loss of Brg1 oncogene [16,17]. > Transcription factors involved in progenitors proliferation and differentiation during pituitary embryogenesis could also be involved in pituitary tumorigenesis. TPIT deficiency is known to result in congenital isolated corticotroph deficiency. Patients with other pituitary transcription factors mutations (PROP1, LHX3, LHX4, HESX1) usually present combined pituitary hormone deficiencies including inconstant corticotroph deficiency. As some of these factors are still expressed at adult age, and their role is not precisely known, it could be tempting to speculate on potential roles of an overexpression of these proteins in pituitary adenomas ontogenesis.

Notes

This provider combines search_papers_by_relevance with snippet_search.
No synthesis or second-stage model call is performed.

Ask OpenScientist

OpenScientist Report

Mappings

Inheritance

Discussions and Knowledge Gaps

Pathophysiology

Pathograph

Phenotypes

Genetic Associations

Medical Actions

Source YAML

References & Deep Research

References

Deep Research

Asta Literature Retrieval: Pathophysiology and clinical mechanisms of AIP-related pituitary adenoma predisposition. Core disease mechanisms, mol...

Relevant Papers

[1] AIP mutations in Brazilian patients with sporadic pituitary adenomas: a single-center evaluation

[2] Landscape of Molecular Events in Pituitary Apoplexy

[3] Novel Insights into Pituitary Tumorigenesis: Genetic and Epigenetic Mechanisms

[4] Aggressive prolactinoma in a child related to germline mutation in the ARYL hydrocarbon receptor interacting protein (AIP) gene.

[5] Childhood Multiple Endocrine Neoplasia (MEN) Syndromes: Genetics, Clinical Heterogeneity and Modifying Genes

[6] Expression and Clinical Significance of miR-26a and Pleomorphic Adenoma Gene 1 (PLAG1) in Invasive Pituitary Adenoma

[7] Isolated familial somatotropinoma: 11q13-loh and gene/protein expression analysis suggests a possible involvement of aip also in non-pituitary tumorigenesis

[8] Macroprolactinoma in a Patient With Schizophrenia: A Therapeutic Challenge

[9] Aryl hydrocarbon receptor (AHR) is a potential tumour suppressor in pituitary adenomas

[10] The Mechanism and Pathways of Dopamine and Dopamine Agonists in Prolactinomas

[11] Dopamine and Somatostatin Analogues Resistance of Pituitary Tumors: Focus on Cytoskeleton Involvement

[12] Molecular subtypes of adamantinomatous craniopharyngiomas

[13] Benzene and 2-ethyl-phthalate induce proliferation in normal rat pituitary cells

[14] Deciphering USP8’s pivotal role in cancer: mechanisms, clinical insights and contrasts with its function in pituitary adenomas

[15] Somatic Deletion in Exon 10 of Aryl Hydrocarbon Receptor Gene in Human GH-Secreting Pituitary Tumors

[16] Phenotype-Genotype Association Analysis of ACTH-Secreting Pituitary Adenoma and Its Molecular Link to Patient Osteoporosis

[17] CCNB1 affects cavernous sinus invasion in pituitary adenomas through the epithelial–mesenchymal transition

[18] Endocrine disrupting chemicals: effects on pituitary, thyroid and adrenal glands

[19] Special issue on molecular genetics in endocrinology.

[20] Cushing’s disease

Notes